Document:

Blueprint

 

 

 Exhibit 10.1

 

 

INDEMNIFICATION AGREEMENT

 

This Indemnification Agreement (“Agreement”), dated as of _______, 201__, is by and
between CorMedix Inc., a Delaware corporation (the
“Company”) and [___________________] (the
“Indemnitee”).

 

WHEREAS, Indemnitee is [a director/an officer] of the Company [the
Company expects Indemnitee to join the Company as a
director];

 

WHEREAS, both the Company and Indemnitee recognize the increased
risk and burden of litigation and other claims being asserted
against directors and officers of public companies;

 

WHEREAS, the board of directors of the Company (the
“Board”) has determined that enhancing the ability
of the Company to retain and attract as directors and officers the
most capable persons is in the best interests of the Company and
that the Company therefore should seek to assure such persons that
appropriate indemnification and insurance coverage is available;
and

 

WHEREAS, in recognition of the need to provide Indemnitee with
protection against personal liability, in order to procure
Indemnitee’s [continued] service as a [director/officer] of
the Company and to enhance Indemnitee’s ability to serve the
Company in an effective manner, and in order to provide such
protection pursuant to express contract rights (intended to be
enforceable irrespective of, among other things, any amendment to
the Company’s certificate of incorporation or bylaws
(collectively, the “Constituent
Documents”), any change
in the composition of the Board or any change in control or
business combination transaction relating to the Company), the
Company wishes to provide in this Agreement for the indemnification
of, and the advancement of Expenses (as defined in Section
1(f) below) to, Indemnitee as set
forth in this Agreement and to the extent insurance is maintained
for the [continued] coverage of Indemnitee under the
Company’s directors’ and officers’ liability
insurance policies.

 

NOW, THEREFORE, in consideration of the foregoing and the
Indemnitee’s agreement to [continue to] provide services to
the Company, the parties agree as follows:

 

1.  Definitions.
For purposes of this Agreement, the following terms shall have the
following meanings:

 

    (a)  “Beneficial
Owner” has the meaning
given to the term “beneficial owner” in Rule 13d-3
under the Securities Exchange Act of 1934, as amended (the
“Exchange Act”).

 

    (b)  “Change
in Control” means the
occurrence after the date of this Agreement of any of the following
events:

 

(i)  any
Person is or becomes the Beneficial Owner, directly or indirectly,
of securities of the Company representing 25% or more of the
Company’s then outstanding Voting Securities;

 

(ii)  the
consummation of a reorganization, merger or consolidation, unless
immediately following such reorganization, merger or consolidation,
all of the Beneficial Owners of the Voting Securities of the
Company immediately prior to such transaction beneficially own,
directly or indirectly, more than 50% of the combined voting power
of the outstanding Voting Securities of the entity resulting from
such transaction;

 

(iii)  during
any period of two consecutive years beginning after July 31, 2017,
individuals who at the beginning of such period constituted the
Board (including for this purpose any new directors whose election
by the Board or nomination for election by the Company’s
stockholders was approved by a vote of at least two-thirds (2/3) of
the directors then still in office who either were directors at the
beginning of the period or whose election or nomination for
election was previously so approved) cease for any reason to
constitute at least a majority of the Board; or

 

(iv)  the
stockholders of the Company approve a plan of complete liquidation
or dissolution of the Company or an agreement for the sale or
disposition by the Company of all or substantially all of the
Company’s assets. 

   

 (c)  ”Claim” means:

 

(i)  any
threatened, pending or completed action, suit, proceeding or
alternative dispute resolution mechanism, whether civil, criminal,
administrative, arbitrative, investigative or other, and whether
made pursuant to federal, state or other law; or

 

(ii)  any
inquiry, hearing or investigation that the Indemnitee reasonably
determines might lead to the institution of any such action, suit,
proceeding or alternative dispute resolution
mechanism.

 

 

 

 

    (d)  “Delaware
Court” shall have the
meaning ascribed to it in Section 8(e) below.

 

    (e)  “Disinterested
Director” means a
director of the Company who is not and was not a party to the Claim
in respect of which indemnification is sought by
Indemnitee.

 

    (f)  “Expenses”
means any and all expenses, including attorneys’ and
experts’ fees, court costs, transcript costs, travel
expenses, duplicating, printing and binding costs, telephone
charges, and all other costs and expenses incurred in connection
with investigating, defending, being a witness in or participating
in (including on appeal), or preparing to defend, be a witness or
participate in, any Claim. Expenses also shall include (i) Expenses
incurred in connection with any appeal resulting from any Claim,
including without limitation the premium, security for, and other
costs relating to any cost bond, supersedeas bond, or other appeal
bond or its equivalent, and (ii) for purposes of Section 4 only,
Expenses incurred by Indemnitee in connection with the
interpretation, enforcement or defense of Indemnitee’s rights
under this Agreement, by litigation or otherwise. Expenses,
however, shall not include amounts paid in settlement by Indemnitee
or the amount of judgments or fines against
Indemnitee.

 

    (g)  “Expense
Advance” means any
payment of Expenses advanced to Indemnitee by the Company pursuant
to Section 3 or Section
4 hereof.

 

    (h)  “Indemnifiable
Event” means any event or
occurrence, whether occurring [before,] on or after the date of
this Agreement, related to the fact that Indemnitee is or was a
director or officer of the Company or any subsidiary of the
Company, or is or was serving at the request of the Company as a
director or officer of any other corporation, limited liability
company, partnership, joint venture, trust or other entity or
enterprise (collectively with the Company,
“Enterprise”) or by reason of an action or inaction by
Indemnitee in any such capacity (whether or not serving in such
capacity at the time any Loss is incurred for which indemnification
can be provided under this Agreement).

 

    (i)  “Independent
Counsel” means a law
firm, or a member of a law firm, that is experienced in matters of
corporation law and neither presently performs, nor in the past two
years has performed, services for either: (i) the Company or
Indemnitee (other than in connection with matters concerning
Indemnitee under this Agreement or of other indemnitees under
similar agreements) or (ii) any other party to the Claim giving
rise to a claim for indemnification hereunder. Notwithstanding the
foregoing, the term “Independent Counsel” shall not
include any person who, under the applicable standards of
professional conduct then prevailing, would have a conflict of
interest in representing either the Company or Indemnitee in an
action to determine Indemnitee’s rights under this
Agreement.

 

    (j)  “Losses”
means any and all Expenses, damages, losses, liabilities,
judgments, fines, penalties (whether civil, criminal or other),
ERISA excise taxes, amounts paid or payable in settlement,
including any interest, assessments, and all other charges paid or
payable in connection with investigating, defending, being a
witness in or participating in (including on appeal), or preparing
to defend, be a witness or participate in, any
Claim.

 

    (k)  “Person”
means any individual, corporation, firm, partnership, joint
venture, limited liability company, estate, trust, business
association, organization, governmental entity or other entity and
includes the meaning set forth in Sections 13(d) and 14(d) of the
Exchange Act.

 

    (l)  “Standard
of Conduct Determination”
shall have the meaning ascribed to it in Section 8(b)
below.

 

    (m)  “Voting
Securities” means any
securities of the Company that vote generally in the election of
directors.

 

2.  Indemnification.
Subject to Section 8 and
Section 9 of this Agreement, the
Company shall indemnify Indemnitee, to the fullest extent permitted
by the laws of the State of Delaware in effect on the date hereof,
or as such laws may from time to time hereafter be amended to
increase the scope of such permitted indemnification, against any
and all Losses if Indemnitee was or is or becomes a party to or
participant in, or is threatened to be made a party to or
participant in, any Claim by reason of or arising in part out of an
Indemnifiable Event, including, without limitation, Claims brought
by or in the right of the Company, Claims brought by third parties,
and Claims in which the Indemnitee is solely a
witness.

 

3.  Advancement of
Expenses. Indemnitee shall have
the right to advancement by the Company, prior to the final
disposition of any Claim by final adjudication to which there are
no further rights of appeal, of any and all Expenses actually and
reasonably paid or incurred by Indemnitee in connection with any
Claim arising out of an Indemnifiable Event. Indemnitee’s
right to such advancement is not subject to the satisfaction of any
standard of conduct. Without limiting the generality or effect of
the foregoing, within 30 days after any request by Indemnitee, the
Company shall, in accordance with such request, (a) pay such
Expenses on behalf of Indemnitee, (b) advance to Indemnitee funds
in an amount sufficient to pay such Expenses, or (c) reimburse
Indemnitee for such Expenses. In connection with any request for
Expense Advances, Indemnitee shall not be required to provide any
documentation or information to the extent that the provision
thereof would undermine or otherwise jeopardize attorney-client
privilege. In connection with any request for Expense Advances,
Indemnitee shall execute and deliver to the Company an undertaking
(which shall be accepted without reference to Indemnitee’s
ability to repay the Expense Advances), in the form attached hereto
as Exhibit
A, to repay any amounts paid,
advanced, or reimbursed by the Company for such Expenses to the
extent that it is ultimately determined, following the final
disposition of such Claim, that Indemnitee is not entitled to
indemnification hereunder. Indemnitee’s obligation to
reimburse the Company for Expense Advances shall be unsecured and
no interest shall be charged thereon.

 

4.  Indemnification for
Expenses in Enforcing Rights.
To the fullest extent allowable under applicable law, the Company
shall also indemnify against, and, if requested by Indemnitee,
shall advance to Indemnitee subject to and in accordance
with Section 3, any Expenses
actually and reasonably paid or incurred by Indemnitee in
connection with any action or proceeding by Indemnitee for (a)
indemnification or reimbursement or advance payment of Expenses by
the Company under any provision of this Agreement, or under any
other agreement or provision of the Constituent Documents now or
hereafter in effect relating to Claims relating to Indemnifiable
Events, and/or (b) recovery under any directors’ and
officers’ liability insurance policies maintained by the
Company. However, in the event that Indemnitee is ultimately
determined not to be entitled to such indemnification or insurance
recovery, as the case may be, then all amounts advanced under
this Section 4 shall be repaid.
Indemnitee shall be required to reimburse the Company in the event
that a final judicial determination is made that such action
brought by Indemnitee was frivolous or not made in good
faith.

 

 

 

 

5.  Partial
Indemnity. If Indemnitee is
entitled under any provision of this Agreement to indemnification
by the Company for a portion of any Losses in respect of a Claim
related to an Indemnifiable Event but not for the total amount
thereof, the Company shall nevertheless indemnify Indemnitee for
the portion thereof to which Indemnitee is
entitled.

 

6.  Notification and
Defense of Claims.

 

(a)   Notification of
Claims. Indemnitee shall notify
the Company in writing as soon as practicable of any Claim which
could relate to an Indemnifiable Event or for which Indemnitee
could seek Expense Advances, including a brief description (based
upon information then available to Indemnitee) of the nature of,
and the facts underlying, such Claim. The failure by Indemnitee to
timely notify the Company hereunder shall not relieve the Company
from any liability hereunder unless the Company’s ability to
participate in the defense of such claim was materially and
adversely affected by such failure. If at the time of the receipt
of such notice, the Company has directors’ and
officers’ liability insurance in effect under which coverage
for Claims related to Indemnifiable Events is potentially
available, the Company shall give prompt written notice to the
applicable insurers in accordance with the procedures set forth in
the applicable policies. The Company shall provide to Indemnitee a
copy of such notice delivered to the applicable insurers, and
copies of all subsequent correspondence between the Company and
such insurers regarding the Claim, in each case substantially
concurrently with the delivery or receipt thereof by the
Company.

 

(b)   Defense of
Claims. The Company shall be
entitled to participate in the defense of any Claim relating to an
Indemnifiable Event at its own expense and, except as otherwise
provided below, to the extent the Company so wishes, it may assume
the defense thereof with counsel reasonably satisfactory to
Indemnitee. After notice from the Company to Indemnitee of its
election to assume the defense of any such Claim, the Company shall
not be liable to Indemnitee under this Agreement or otherwise for
any Expenses subsequently directly incurred by Indemnitee in
connection with Indemnitee’s defense of such Claim other than
reasonable costs of investigation or as otherwise provided below.
Indemnitee shall have the right to employ its own legal counsel in
such Claim, but all Expenses related to such counsel incurred after
notice from the Company of its assumption of the defense shall be
at Indemnitee’s own expense; provided, however, that if (i)
Indemnitee’s employment of its own legal counsel has been
authorized by the Company, (ii) Indemnitee has reasonably
determined that there may be a conflict of interest between
Indemnitee and the Company in the defense of such Claim and has
advised the Company in writing of the basis of such determination,
(iii) after a Change in Control, Indemnitee’s employment of
its own counsel has been approved by the Independent Counsel or
(iv) the Company shall not in fact have employed counsel to assume
the defense of such Claim, then Indemnitee shall be entitled to
retain its own separate counsel (but not more than one law firm
plus, if applicable, local counsel in respect of any such Claim)
and all Expenses related to such separate counsel shall be borne by
the Company.

 

7.  Procedure upon
Application for Indemnification. In order to obtain indemnification pursuant to
this Agreement, Indemnitee shall submit to the Company a written
request therefor, including in such request such documentation and
information as is reasonably available to Indemnitee and is
reasonably necessary to determine whether and to what extent
Indemnitee is entitled to indemnification following the final
disposition of the Claim, provided that documentation and
information need not be so provided to the extent that the
provision thereof would undermine or otherwise jeopardize
attorney-client privilege. Indemnification shall be made insofar as
the Company determines Indemnitee is entitled to indemnification in
accordance with Section 8 below.

 

8.  Determination of Right
to Indemnification.

 

    (a)  Mandatory
Indemnification; Indemnification as a Witness.

 

(i)  To the extent that Indemnitee shall
have been successful on the merits or otherwise in defense of any
Claim relating to an Indemnifiable Event or any portion thereof or
in defense of any issue or matter therein, including without
limitation dismissal without prejudice, Indemnitee shall be
indemnified against all Losses relating to such Claim in accordance
with Section 2 to the fullest
extent allowable by law, and no Standard of Conduct Determination
(as defined in Section 8(b))
shall be required.

 

(ii)  To the extent that
Indemnitee’s involvement in a Claim relating to an
Indemnifiable Event is to prepare to serve and serve as a witness,
and not as a party, the Indemnitee shall be indemnified against all
Losses incurred in connection therewith to the fullest extent
allowable by law and no Standard of Conduct Determination (as
defined in Section 8(b)) shall
be required.

 

    (b)  Standard
of Conduct. To the extent that
the provisions of Section 8(a) are inapplicable to a Claim related to an
Indemnifiable Event that shall have been finally disposed of, any
determination of whether Indemnitee has satisfied any applicable
standard of conduct under Delaware law that is a legally required
condition to indemnification of Indemnitee hereunder against Losses
relating to such Claim and any determination that Expense Advances
must be repaid to the Company (a “Standard of Conduct
Determination”) shall be
made as follows:

 

(i)  if
no Change in Control has occurred, (A) by a majority vote of the
Disinterested Directors, even if less than a quorum of the Board,
(B) by a committee of Disinterested Directors designated by a
majority vote of the Disinterested Directors, even though less than
a quorum or (C) if there are no such Disinterested Directors, by
Independent Counsel in a written opinion addressed to the Board, a
copy of which shall be delivered to Indemnitee; and

 

(ii)  if
a Change in Control shall have occurred, (A) if the Indemnitee so
requests in writing, by a majority vote of the Disinterested
Directors, even if less than a quorum of the Board or (B)
otherwise, by Independent Counsel in a written opinion addressed to
the Board, a copy of which shall be delivered to
Indemnitee.

 

The
Company shall indemnify and hold harmless Indemnitee against and,
if requested by Indemnitee, shall reimburse Indemnitee for, or
advance to Indemnitee, within 45 days of such request, any and all
Expenses incurred by Indemnitee in cooperating with the person or
persons making such Standard of Conduct Determination.

 

 

 

 

    (c)  Making
the Standard of Conduct Determination. The Company shall use its reasonable best
efforts to cause any Standard of Conduct Determination required
under Section 8(b) to be made
as promptly as practicable. If the person or persons designated to
make the Standard of Conduct Determination under Section
8(b) shall not have made a
determination within 30 days after the later of (A) receipt by the
Company of a written request from Indemnitee for indemnification
pursuant to Section 7 (the date
of such receipt being the “Notification
Date”) and (B) the
selection of an Independent Counsel, if such determination is to be
made by Independent Counsel, then Indemnitee shall be deemed to
have satisfied the applicable standard of conduct; provided that
such 30-day period may be extended for a reasonable time, not to
exceed an additional 30 days, if the person or persons making such
determination in good faith requires such additional time to obtain
or evaluate information relating thereto. Notwithstanding anything
in this Agreement to the contrary, no determination as to
entitlement of Indemnitee to indemnification under this Agreement
shall be required to be made prior to the final disposition of any
Claim.

 

    (d)  Payment
of Indemnification. If, in
regard to any Losses:

 

(i)  Indemnitee shall be entitled to
indemnification pursuant to Section 9(a);

 

(ii)  no
Standard Conduct Determination is legally required as a condition
to indemnification of Indemnitee hereunder; or

 

(iii)  Indemnitee has been determined or
deemed pursuant to Section 8(b) or Section 8(c) to have satisfied the Standard of Conduct
Determination,

 

then
the Company shall pay to Indemnitee, within five days after the
later of (A) the Notification Date or (B) the earliest date on
which the applicable criterion specified in clause (i), (ii) or
(iii) is satisfied, an amount equal to such Losses.

 

    (e)  Selection
of Independent Counsel for Standard of Conduct
Determination. If a Standard of
Conduct Determination is to be made by Independent Counsel pursuant
to Section 8(b)(i), the
Independent Counsel shall be selected by the Board of Directors,
and the Company shall give written notice to Indemnitee advising
[him/her] of the identity of the Independent Counsel so selected.
If a Standard of Conduct Determination is to be made by Independent
Counsel pursuant to Section 8.1(b)(ii), the Independent Counsel shall be selected by
Indemnitee, and Indemnitee shall give written notice to the Company
advising it of the identity of the Independent Counsel so selected.
In either case, Indemnitee or the Company, as applicable, may,
within five days after receiving written notice of selection from
the other, deliver to the other a written objection to such
selection; provided, however, that such objection may be asserted
only on the ground that the Independent Counsel so selected does
not satisfy the criteria set forth in the definition of
“Independent Counsel” in Section
1(i), and the objection shall set
forth with particularity the factual basis of such assertion.
Absent a proper and timely objection, the person or firm so
selected shall act as Independent Counsel. If such written
objection is properly and timely made and substantiated, (i) the
Independent Counsel so selected may not serve as Independent
Counsel unless and until such objection is withdrawn or a court has
determined that such objection is without merit; and (ii) the
non-objecting party may, at its option, select an alternative
Independent Counsel and give written notice to the other party
advising such other party of the identity of the alternative
Independent Counsel so selected, in which case the provisions of
the two immediately preceding sentences, the introductory clause of
this sentence and numbered clause (i) of this sentence shall apply
to such subsequent selection and notice. If applicable, the
provisions of clause (ii) of the immediately preceding sentence
shall apply to successive alternative selections. If no Independent
Counsel that is permitted under the foregoing provisions of
this Section 8(e) to make the
Standard of Conduct Determination shall have been selected within
20 days after the Company gives its initial notice pursuant to the
first sentence of this Section 9(e) or Indemnitee gives its initial notice pursuant to
the second sentence of this Section 8(e), as the case may be, either the Company or
Indemnitee may petition the Court of Chancery of the State of
Delaware (“Delaware
Court”) to resolve any
objection which shall have been made by the Company or Indemnitee
to the other’s selection of Independent Counsel and/or to
appoint as Independent Counsel a person to be selected by the Court
or such other person as the Court shall designate, and the person
or firm with respect to whom all objections are so resolved or the
person or firm so appointed will act as Independent Counsel. In all
events, the Company shall pay all of the reasonable fees and
expenses of the Independent Counsel incurred in connection with the
Independent Counsel’s determination pursuant to
Section 8(b).

 

    (f)  Presumptions
and Defenses.

 

(i)  Indemnitee’s
Entitlement to Indemnification.
In making any Standard of Conduct Determination, the person or
persons making such determination shall presume that Indemnitee has
satisfied the applicable standard of conduct and is entitled to
indemnification, and the Company shall have the burden of proof to
overcome that presumption and establish that Indemnitee is not so
entitled. Any Standard of Conduct Determination that is adverse to
Indemnitee may be challenged by the Indemnitee in the Delaware
Court. No determination by the Company (including by its directors
or any Independent Counsel) that Indemnitee has not satisfied any
applicable standard of conduct may be used as a defense to any
legal proceedings brought by Indemnitee to secure indemnification
or reimbursement or advance payment of Expenses by the Company
hereunder or create a presumption that Indemnitee has not met any
applicable standard of conduct.

 

(ii)  Reliance as a Safe
Harbor. For purposes of this
Agreement, and without creating any presumption as to a lack of
good faith if the following circumstances do not exist, Indemnitee
shall be deemed to have acted in good faith and in a manner he or
she reasonably believed to be in or not opposed to the best
interests of the Company if Indemnitee’s actions or omissions
to act are taken in good faith reliance upon the records of the
Company, including its financial statements, or upon information,
opinions, reports or statements furnished to Indemnitee by the
officers or employees of the Company or any of its subsidiaries in
the course of their duties, or by committees of the Board or by any
other Person (including legal counsel, accountants and financial
advisors) as to matters Indemnitee reasonably believes are within
such other Person’s professional or expert competence and who
has been selected with reasonable care by or on behalf of the
Company. In addition, the knowledge and/or actions, or failures to
act, of any directors, officer, agent or employee of the Company
shall not be imputed to Indemnitee for purposes of determining the
right to indemnity hereunder.

 

(iii)  No Other
Presumptions. For purposes of
this Agreement, the termination of any Claim by judgment, order,
settlement (whether with or without court approval) or conviction,
or upon a plea of nolo contendere or its equivalent, will not
create a presumption that Indemnitee did not meet any applicable
standard of conduct or have any particular belief, or that
indemnification hereunder is otherwise not
permitted.

 

(iv)  Defense to
Indemnification and Burden of Proof. It shall be a defense to any action brought by
Indemnitee against the Company to enforce this Agreement (other
than an action brought to enforce a claim for Losses incurred in
defending against a Claim related to an Indemnifiable Event in
advance of its final disposition) that it is not permissible under
applicable law for the Company to indemnify Indemnitee for the
amount claimed. In connection with any such action or any related
Standard of Conduct Determination, the burden of proving such a
defense or that the Indemnitee did not satisfy the applicable
standard of conduct shall be on the Company.

 

(v)  Resolution of
Claims. The Company
acknowledges that a settlement or other disposition short of final
judgment may be successful on the merits or otherwise for purposes
of Section 8.1(a)(i) if it
permits a party to avoid expense, delay, distraction, disruption
and uncertainty. In the event that any Claim relating to an
Indemnifiable Event to which Indemnitee is a party is resolved in
any manner other than by adverse judgment against Indemnitee
(including, without limitation, settlement of such action, claim or
proceeding with or without payment of money or other consideration)
it shall be presumed that Indemnitee has been successful on the
merits or otherwise for purposes of Section 8.1(a)(i).
The Company shall have the burden of
proof to overcome this presumption.

 

 

 

 

 

9.  Exclusions from
Indemnification.
Notwithstanding anything in this Agreement to the contrary, the
Company shall not be obligated to:

 

    (a)  indemnify
or advance funds to Indemnitee for Expenses or Losses with respect
to proceedings initiated by Indemnitee, including any proceedings
against the Company or its directors, officers, employees or other
indemnitees and not by way of defense, except: 

 

(i)  proceedings referenced in
Section 4 above (unless a court of
competent jurisdiction determines that each of the material
assertions made by Indemnitee in such proceeding was not made in
good faith or was frivolous); or

 

(ii)  where
the Company has joined in or the Board has consented to the
initiation of such proceedings.

 

    (b)  indemnify
Indemnitee if a final decision by a court of competent jurisdiction
determines that such indemnification is prohibited by applicable
law.

 

    (c)  indemnify
Indemnitee for the disgorgement of profits arising from the
purchase or sale by Indemnitee of securities of the Company in
violation of Section 16(b) of the Exchange Act, or any similar
successor statute.

 

10.  Settlement of
Claims. The Company shall not
be liable to Indemnitee under this Agreement for any amounts paid
in settlement of any threatened or pending Claim related to an
Indemnifiable Event effected without the Company’s prior
written consent, which shall not be unreasonably withheld;
provided, however, that if a Change in Control has occurred, the
Company shall be liable for indemnification of the Indemnitee for
amounts paid in settlement if an Independent Counsel has approved
the settlement. The Company shall not settle any Claim related to
an Indemnifiable Event in any manner that would impose any Losses
on the Indemnitee without the Indemnitee’s prior written
consent.

 

11.  Duration.
All agreements and obligations of the Company contained herein
shall continue during the period that Indemnitee is a director or
officer of the Company (or is serving at the request of the Company
as a director or officer of another Enterprise) and shall continue
thereafter (i) so long as Indemnitee may be subject to any possible
Claim relating to an Indemnifiable Event (including any rights of
appeal thereto) and (ii) throughout the pendency of any proceeding
(including any rights of appeal thereto) commenced by Indemnitee to
enforce or interpret his or her rights under this Agreement, even
if, in either case, he or she may have ceased to serve in such
capacity at the time of any such Claim or
proceeding.

 

12.  Non-Exclusivity.
The rights of Indemnitee hereunder will be in addition to any other
rights Indemnitee may have under the Constituent Documents, the
General Corporation Law of the State of Delaware, any other
contract or otherwise (collectively, “Other Indemnity
Provisions”); provided,
however, that (a) to the extent that Indemnitee otherwise would
have any greater right to indemnification under any Other Indemnity
Provision, Indemnitee will be deemed to have such greater right
hereunder and (b) to the extent that any change is made to any
Other Indemnity Provision which permits any greater right to
indemnification than that provided under this Agreement as of the
date hereof, Indemnitee will be deemed to have such greater right
hereunder. The Company will not adopt any amendment to any of the
Constituent Documents the effect of which would be to deny,
diminish or encumber Indemnitee’s right to indemnification
under this Agreement or any Other Indemnity
Provision.

 

13.  Liability
Insurance. For the duration of
Indemnitee’s service as a [director/officer] of the Company,
and thereafter for so long as Indemnitee shall be subject to any
pending Claim relating to an Indemnifiable Event, the Company shall
use commercially reasonable efforts (taking into account the scope
and amount of coverage available relative to the cost thereof and
the Company’s ability to pay such cost) to continue to
maintain in effect policies of directors’ and officers’
liability insurance providing coverage that is at least
substantially comparable in scope and amount to that provided by
the Company’s current policies of directors’ and
officers’ liability insurance. In all policies of
directors’ and officers’ liability insurance maintained
by the Company, Indemnitee shall be named as an insured in such a
manner as to provide Indemnitee the same rights and benefits as are
provided to the most favorably insured of the Company’s
directors, if Indemnitee is a director, or of the Company’s
officers, if Indemnitee is an officer (and not a director) by such
policy. Upon request, the Company will provide to Indemnitee copies
of all directors’ and officers’ liability insurance
applications, binders, policies, declarations, endorsements and
other related materials.

 

14.  No Duplication of
Payments. The Company shall not
be liable under this Agreement to make any payment to Indemnitee in
respect of any Losses to the extent Indemnitee has otherwise
received payment under any insurance policy, the Constituent
Documents, Other Indemnity Provisions or otherwise of the amounts
otherwise indemnifiable by the Company
hereunder.

 

15.  Subrogation.
In the event of payment to Indemnitee under this Agreement, the
Company shall be subrogated to the extent of such payment to all of
the rights of recovery of Indemnitee. Indemnitee shall execute all
papers required and shall do everything that may be necessary to
secure such rights, including the execution of such documents
necessary to enable the Company effectively to bring suit to
enforce such rights.

 

16.  Amendments.
No supplement, modification or amendment of this Agreement shall be
binding unless executed in writing by both of the parties hereto.
No waiver of any of the provisions of this Agreement shall be
binding unless in the form of a writing signed by the party against
whom enforcement of the waiver is sought, and no such waiver shall
operate as a waiver of any other provisions hereof (whether or not
similar), nor shall such waiver constitute a continuing waiver.
Except as specifically provided herein, no failure to exercise or
any delay in exercising any right or remedy hereunder shall
constitute a waiver thereof.

 

17.  Binding
Effect. This Agreement shall be
binding upon and inure to the benefit of and be enforceable by the
parties hereto and their respective successors (including any
direct or indirect successor by purchase, merger, consolidation or
otherwise to all or substantially all of the business and/or assets
of the Company), assigns, spouses, heirs and personal and legal
representatives. The Company shall require and cause any successor
(whether direct or indirect by purchase, merger, consolidation or
otherwise) to all, substantially all or a substantial part of the
business and/or assets of the Company, by written agreement in form
and substance reasonably satisfactory to Indemnitee, expressly to
assume and agree to perform this Agreement in the same manner and
to the same extent that the Company would be required to perform if
no such succession had taken place.

 

18.  Severability.
The provisions of this Agreement shall be severable in the event
that any of the provisions hereof (including any portion thereof)
are held by a court of competent jurisdiction to be invalid,
illegal, void or otherwise unenforceable, and the remaining
provisions shall remain enforceable to the fullest extent permitted
by law. Upon such determination that any term or other provision is
invalid, illegal or unenforceable, the parties hereto shall
negotiate in good faith to modify this Agreement so as to effect
the original intent of the parties as closely as possible in a
mutually acceptable manner in order that the transactions
contemplated hereby be consummated as originally contemplated to
the extent possible.

 

 

 

 

19.  Notices.
All notices, requests, demands and other communications hereunder
shall be in writing and shall be deemed to have been duly given if
delivered by hand, against receipt, or mailed, by postage prepaid,
certified or registered mail:

 

    (a)  if
to Indemnitee, to the address set forth on the signature page
hereto.

 

    (b)  if
to the Company, to: CorMedix Inc.

 

                    Attn:
Chief Financial Officer

                   
1430
U.S. Highway 206, Suite 200

                   
Bedminster,
New Jersey 07921

    

Notice of change of address shall be effective only when given in
accordance with this Section. All notices complying with this
Section shall be deemed to have been received on the date of hand
delivery or on the third business day after mailing.

 

20.  Governing Law and
Forum. This Agreement shall be
governed by and construed and enforced in accordance with the laws
of the State of Delaware applicable to contracts made and to be
performed in such state without giving effect to its principles of
conflicts of laws. The Company and Indemnitee hereby irrevocably
and unconditionally: (a) agree that any action or proceeding
arising out of or in connection with this Agreement shall be
brought only in the Delaware Court and not in any other state or
federal court in the United States, (b) consent to submit to the
exclusive jurisdiction of the Delaware Court for purposes of any
action or proceeding arising out of or in connection with this
Agreement, and (c) waive, and agree not to plead or make, any claim
that the Delaware Court lacks venue or that any such action or
proceeding brought in the Delaware Court has been brought in an
improper or inconvenient forum.

 

21.  Headings.
The headings of the sections and paragraphs of this Agreement are
inserted for convenience only and shall not be deemed to constitute
part of this Agreement or to affect the construction or
interpretation thereof.

 

22.  Counterparts.
This Agreement may be executed in one or more counterparts, each of
which shall for all purposes be deemed to be an original, but all
of which together shall constitute one and the same
Agreement.

 

 

 

 

 

IN WITNESS WHEREOF, the parties hereto have executed this Agreement
as of the date first above written.

 

	
 

	

CorMedix
Inc.

 

 

 

 

	
 

	

By:
______________________________

Name:
____________________________

Title:
_____________________________

 

 

 

 

 

	
 

	

INDEMNITEE

 

 

 

 

	
 

	

_______________________________

Name:
__________________________

Address:________________________

_______________________________

_______________________________

 

 

 

 

 

 

 

 

 

EXHIBIT A

 

FORM OF UNDERTAKING TO REPAY ADVANCEMENT OF EXPENSES

 

CorMedix
Inc. 

Attn:
Chief Financial Officer

1430
U.S. Highway 206, Suite 200

Bedminster,
New Jersey 07921

 

 

Re: Undertaking to Repay Advancement of Expenses

 

Dear [ADDRESSEE]:

 

This undertaking is being provided pursuant to that certain
Indemnification Agreement, dated [___], 201_, by and between
CorMedix Inc., a Delaware corporation (the
“Company”), and the undersigned as Indemnitee (the
“Indemnification
Agreement”). Terms used
herein and not otherwise defined shall have the meanings ascribed
to them in the Indemnification Agreement. Pursuant to the
Indemnification Agreement, among other things, I am entitled to the
advancement of Expenses paid or incurred in connection with Claims
relating to Indemnifiable Events.

 

I have become subject to [DESCRIPTION OF PROCEEDING] (the
“Proceeding”) based on my status as [an officer/[TITLE
OF OFFICER]/a director] of the Company/alleged actions or failures
to act in my capacity as [an officer/[TITLE OF OFFICER]/a director]
of the Company. This undertaking also constitutes notice to the
Company of the Proceeding pursuant to Section 6 of the
Indemnification Agreement. The following is a brief description of
the [current status of the] Proceeding:

 

[DESCRIPTION OF PROCEEDING]

 

Pursuant to Section 3 of the Indemnification Agreement, the Company
can (a) pay such Expenses on my behalf, (b) advance funds in an
amount sufficient to pay such Expenses, or (c) reimburse me for
such Expenses. Pursuant to Section 3 of the Indemnification
Agreement, I hereby request an Expense Advance in connection with
the Proceeding. The Expenses for which advances are requested are
as follows:

 

[DESCRIPTION OF EXPENSES]

 

[In connection with the request for Expense Advances set out above,
I hereby undertake to repay any amounts paid, advanced or
reimbursed by the Company for such Expense Advances to the extent
that it is ultimately determined that I am not entitled to
indemnification under the Indemnification Agreement.

 

This undertaking shall be governed by and construed in accordance
with the laws of the State of Delaware, without regard to the
principles of conflicts of laws thereof.

 

 

	
 

	

Very
truly yours,

 

 

 

 

	
 

	

______________________________

Name:
________________________

[Title:]
________________________

 

 

 

 

 

 

[cc: [ADD PARTY NAME AND ADDRESS AS NECESSARY]]EX-10.33

 Exhibit 10.33 

CONFIDENTIAL TREATMENT REQUESTED 
  

 
 May 12, 2017 
 Jason Kim

 Chief Financial Officer 
 Molecular Templates, Inc. 

9301 Amberglen Blvd., Suite 100 
 Austin, Texas 78729 

Dear Jason: 
 It is my pleasure to inform you that Molecular
Templates has been approved for a no-cost extension for grant ID: CC121020. Details are as follows: 
  

			
	Contract Start Date:	  	01 Dec 2011
	Original Contract End Date:	  	30 Nov 2015
	No-Cost Extension:	  	30 May 2016
	No-Cost Extension:	  	30 May 2017
	No-Cost Extension:	  	30 May 2018

 Please let me know if you have any questions by calling me at 512/305-7676. I look forward to continuing to work with you and
your staff. 
 Best regards, 
 /S/ Cathy Allen 

Cathy Allen 
 Program Manager 

Product Development Research Program 
 Cancer Prevention Research
Institute of Texas 
 Callen@cprit.texas.state 

Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

  
 1 

 Exhibit 10.33 

CONFIDENTIAL TREATMENT REQUESTED 
  

 
 STATE OF TEXAS 
 COUNTY OF
TRAVIS 
 This CANCER RESEARCH GRANT CONTRACT (“Contract”) is by and between the Cancer Prevention and Research Institute of
Texas (“CPRIT”), hereinafter referred to as the “INSTITUTE”, acting through its Executive Director, and Molecular Templates, Inc., hereinafter referred to as the
“RECIPIENT”, acting through its authorized signing official. 
 RECITALS 

WHEREAS, pursuant to TEX. HEALTH & SAFETY CODE, Ch. 102, the INSTITUTE may make grants to public and private persons in this state for research into
the causes and cures for all types of cancer in humans; facilities for use in research into the causes and cures for cancer; research to develop therapies, protocols, medical pharmaceuticals, or procedures for the cure or substantial mitigation of
all types of cancer; and cancer prevention and control programs. 
 WHEREAS, Article III, Section 67 of the Texas Constitution expressly authorizes the
State of Texas to sell general obligation bonds on behalf of the INSTITUTE and for the INSTITUTE to use the proceeds from the sale of the bonds for the purposes of cancer research and prevention programs in this state. 

WHEREAS, the INSTITUTE issued a request for applications for RFA C-12-COMP-1: Company Commercialization Awards on or about January 2011. 

WHEREAS, pursuant to TEX. HEALTH & SAFETY CODE § 102.251, and after a review by the INSTITUTE’s scientific research and prevention program
committees, the INSTITUTE’s Executive Director has approved a Grant (defined below) to be awarded to the RECIPIENT. 
 WHEREAS, to ensure that the
Grant provided to the RECIPIENT pursuant to this Contract is utilized in a manner consistent with Tex. Const. Article III, Section 67 and other laws, and in exchange for receiving such Grant, the RECIPIENT agrees to comply with certain
conditions and deliver certain performance. 
 WHEREAS, the RECIPIENT and the INSTITUTE desire to set forth herein the provisions relating to the awarding
of such monies and the disbursement thereof to the RECIPIENT. 
 IN CONSIDERATION of the Grant and the premises, covenants, agreements, and
provisions contained in this Contract, the parties agree to the following terms and conditions: 

  
 Portions of
this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the
Securities Act of 1933, as amended. 

  
 2 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 Article I 

DEFINITIONS 
 The following terms shall
have the following meaning throughout this Contract and any Attachments and amendments. Other terms may be defined elsewhere in this Contract. 
 (1)
Collaborator – any entity other than the RECIPIENT having one or more personnel participating in the Project and (a) designated as a collaborator in the application submitted by the RECIPIENT requesting the Grant funds
awarded by the INSTITUTE, or (b) otherwise approved in writing as a collaborator by the INSTITUTE. 
 (2) Contractor – any person or
entity, other than a Collaborator or the RECIPIENT (or their respective personnel), who is contracted by the RECIPIENT to perform activities for the Project. 

(3) Equipment - an article of tangible, nonexpendable personal property having a useful life of more than one year and an acquisition cost of
$5,000 or more per unit. 
 (4) Grant – the funding assistance authorized by TEX. HEALTH & SAFETY CODE, Ch. 102 in the amount
specified in Section 2.01 and awarded by the INSTITUTE to the RECIPIENT to carry out the Project pursuant to the terms and conditions of this Contract. 

(5) Indirect Costs – the expenses of doing business that are not readily identified with a particular grant, contract, project, function or
activity, but are necessary for the general operation of the organization or the performance of the organization’s activities. 
 (6)
Institute-Funded Activity – all aspects of work conducted on or as part of the Project. 
 (7) Non-Profit Organization
– a university or other institution of higher education or an organization of the type described in 501(c)(3) of the Internal Revenue Code of 1986, as amended (26 U.S.C. 501 (c)(3)) and exempt from taxation under 501 (a) of the
Internal Revenue Code (26 U.S.C. 501 (a)) or any nonprofit scientific or educational organization qualified under a state nonprofit organization statute. 

(8) Principal Investigator/Program Director – the individual designated by the RECIPIENT to direct the Project who is principally
responsible and accountable to the RECIPIENT and the INSTITUTE for the proper conduct of the Project. References herein to “Principal Investigator/Program Director” include Co-Principal Investigators or Co-Program Directors as well. The
Principal Investigator/Program Director and Co-Principal Investigators or Co-Program Directors are set forth on Attachment A. 
 (9) Project
– the activities specified or generally described in the Scope of Work or otherwise in this Contract (including without limitation any of the Attachments to the Contract) that are approved by the INSTITUTE for funding, regardless of
whether the INSTITUTE funding constitutes all or only a portion of the financial support necessary to carry them out. 
 (10) Recipient Personnel
– The RECIPIENT’s Principal Investigator/Program Director and RECIPIENT’s employees and consultants working on the Project. 

  
 Portions of
this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the
Securities Act of 1933, as amended. 

  
 3 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 Article II 

GRANT AWARD 
 Section 2.01 Award of
Monies. In accordance with the provisions of this Contract, the INSTITUTE shall disburse the proceeds of the Grant to the RECIPIENT in an amount not to exceed $10,600,000 to be used solely for the Project. This award is subject to
compliance with the Scope of Work and demonstration of progress towards achievement of the milestones set forth in Section 2.02. The INSTITUTE, in its sole discretion, may award supplemental funding not to exceed ten percent (10%) of the
total Grant amount based upon progress made by the RECIPIENT pursuant to the Scope of Work. This Grant is not intended to be a loan of money. 

Section 2.02 Scope of Work and Milestones. The RECIPIENT shall perform the Project in accordance with this Agreement and as outlined in
Application CC121020 submitted by the RECIPIENT and approved by the INSTITUTE. The RECIPIENT shall conduct the Project within the State of Texas with Texas-based employees, Contractors and/or Collaborators unless otherwise specified in the
Scope of Work or the Approved Budget. The INSTITUTE and the RECIPIENT hereby adopt the terms of Attachment A in their entirety, incorporate them as if fully set forth herein, and agree that the Project description, goals, timeline and milestones
included as Attachment A accurately reflect the Scope of Work of the Project to be undertaken by the RECIPIENT (the “Scope of Work”) and the milestones expected to be achieved. RECIPENT and the INSTITUTE mutually agree that
the outcome of scientific research is unpredictable and cannot be guaranteed. The RECIPIENT shall use commercially reasonable efforts to complete the goals of the Project pursuant to the timeline reflected in Attachment A and shall timely notify the
INSTITUTE if circumstances occur that materially and adversely affect completion thereof. Modifications, if any, to the Scope of Work must be agreed to in writing by both parties as set forth in Section 2.06 “Amendments and
Modifications” herein. Material changes to the Scope of Work include, but are not limited to, changes in key personnel involved with the Project, the site of the Project, and the milestones expected to be achieved. 

Section 2.03 Contract Term. The Contract shall be effective as of December 1, 2011 (the “Effective Date”) and
terminate on November 30, 2014 or in accordance with the Contract termination provisions set forth in Article VIII herein, whichever shall occur first (the “Termination Date”). Unless otherwise approved by the
INSTITUTE as evidenced by written communication from the INSTITUTE to the RECIPIENT and appended to the Contract, Grant funds distributed pursuant to the Contract shall be expended no earlier than the Effective Date or subsequent to the Termination
Date. If, as of the Termination Date, the RECIPIENT has not used Grant money awarded by the INSTITUTE for permissible services, expenses, or costs related to the Project and has not received approval from the INSTITUTE for a no cost extension to the
contract term pursuant to Section 3.11 “Carry Forward of Unspent Funds and No Cost Extension” herein, then the RECIPIENT shall not be entitled to retain such unused Grant funds from the INSTITUTE. Certain obligations as set forth in
Section 9.09 of this Contract shall extend beyond the Termination Date. 
 Section 2.04 Contract Documentation. The Contract between
the INSTITUTE and the RECIPIENT shall consist of this final, executed Contract, including the following Attachments to the Contract, all of which are hereby incorporated by reference: 

 

	 	(a)	Attachment A – Project Description, Goals and Timeline 

  
 Portions of
this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the
Securities Act of 1933, as amended. 

  
 4 

 CONFIDENTIAL TREATMENT REQUESTED 

 

	 	(b)	Attachment B – Approved Budget, including changes approved by the INSTITUTE subsequent to execution of the Contract. 

  

	 	(c)	Attachment C – Assurances and Certifications 

  

	 	(d)	Attachment D – Intellectual Property and Revenue Sharing 

  

	 	(e)	Attachment E – Reporting Requirements 

  

	 	(f)	Attachment F – Approved Amendments to Contract, excluding budget amendments reflected in Attachment B. 

Section 2.05 Entire Agreement. All agreements, covenants, representations, certifications and understandings between the parties hereto concerning
this Contract have been merged into this written Contract. No prior or contemporaneous representation, agreement or understanding, express or implied, oral or otherwise, of the parties or their agents that may have related to the subject matter
hereof in any way shall be valid or enforceable unless embodied in this Contract. 
 Section 2.06 Amendments and Modifications. Requested
amendments and modifications to the Contract must be submitted in writing to the INSTITUTE for review and approval (such approval shall not be unreasonably withheld.) Amendments and modifications (including alterations, additions, deletions,
assignments and extensions) to the terms of this Contract shall be made solely in writing and shall be executed by both parties. The approved amendment shall be reflected in Attachment A if it is change to the Scope of Work, or as part of Attachment
B if it is a budget amendment, or as part of Attachment F for all other changes. No handwritten changes to this Contract shall be effective unless initialed and dated by authorized signatories of both parties. 

Section 2.07 Relationship of the Parties. The RECIPIENT shall be responsible for the conduct of the Project that is the subject of this Contract
and shall direct the activities and at all times be responsible for the performance of Recipient Personnel, Collaborators, Contractors and other agents. The INSTITUTE does not assume responsibility for the conduct of the Project or any
Institute-Funded Activity that is the subject of this Contract. The INSTITUTE and the RECIPIENT shall perform their respective obligations under this Contract as independent contractors and not as agents, employees, partners, joint venturers, or
representatives of the other party. Neither party is permitted to make representations or commitments that bind the other party. 

Section 2.08 Subcontracting. Any and all subcontracts entered into by the RECIPIENT in relation to the performance of activities under the Project
shall be in writing and shall be subject to the requirements of this Contract. Without in any way limiting the foregoing, the RECIPIENT shall enter into and maintain a written agreement with each such permitted Contractor with terms and conditions
sufficient to ensure the RECIPIENT fully complies with the terms of this Contract, including without limitation the terms set forth in Attachments C, D, and E. The RECIPIENT agrees that it shall be responsible to the INSTITUTE for the performance of
and payment to any Contractor. Any reimbursements made by the RECIPIENT to a Contractor shall be made in accordance with the applicable provisions of TEX. GOV’T. CODE, Ch. 2251. 

Section 2.09 Transfer or Assignment by the Recipient. This Contract is not transferable or otherwise

  
 Portions of
this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the
Securities Act of 1933, as amended. 

  
 5 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 
assignable by the RECIPIENT, whether by operation of law or otherwise, without the prior written consent of the INSTITUTE, except as provided in this Section 2.09. Any such attempted
transfer or assignment without the prior written consent of the INSTITUTE (except as provided in this Section 2.09) shall be null, void and of no effect. For purposes of this section, an assignment or transfer of this Contract by the RECIPIENT
in connection with a merger, transfer or sale of all or substantially all of the RECIPIENT’s assets or business related to this Contract or a consolidation, change of control or similar transaction involving the RECIPIENT shall not be deemed to
constitute a transfer or assignment, so long as such action does not impair or otherwise negatively impact the revenue sharing terms in Attachment D. Nothing herein shall be interpreted as superseding the requirement that the Project be undertaken
in Texas with Texas-based employees. 
 If the Principal Investigator leaves the employment of the RECIPIENT or is replaced by the RECIPIENT for any reason
during the course of the Grant with someone who is not already designated a co-Principal Investigator in Attachment A, the RECIPIENT shall notify the INSTITUTE prior to replacing the Principal Investigator. Written approval by the INSTITUTE is
required for the replacement of the Principal Investigator with someone who is not already a co-Principal Investigator in Attachment A, which approval shall not be unreasonably withheld, conditioned or delayed. 

Section 2.10 Representations and Certifications. The RECIPIENT represents and certifies to the best of its knowledge and belief to the INSTITUTE
as follows: 
  

	 	(a)	It has legal authority to enter into, execute, and deliver this Contract, and all documents referred to herein, and it has taken all corporate actions necessary to its execution and delivery of such documents;

  

	 	(b)	It will comply with all of the terms, conditions, provisions, covenants, requirements, and certifications in this Contract, and all other documents incorporated herein by reference; 

 

	 	(c)	It has made no material false statement or misstatement of fact in connection with this Contract and its receipt of the Grant, and all of the information it previously submitted to the INSTITUTE or that it is required
under this Contract to submit to the INSTITUTE relating to the Grant or the disbursement of any of the Grant is and will be true and correct at the time such statement is made; 

 

	 	(d)	It is in compliance in all material respects with provisions of its charter and of the laws of the State of Texas, and of the laws of the jurisdiction in which it was formed, and (i) there are no actions, suits, or
proceedings pending, or threatened, before any judicial body or governmental authority against or affecting its ability to enter into this Contract, or any document referred to herein, or to perform any of the material acts required of it in such
documents and (ii) it is not in default with respect to any order, writ, injunction, decree, or demand of any court or any governmental authority which would impair its ability to enter into this Contract, or any document referred to herein, or
to perform any of the material acts required of it in such documents; 

  

	 	(e)	 Neither the execution and delivery of this Contract or any document referred to herein, nor compliance with any
of the terms, conditions, requirements, or provisions contained in this Contract or any documents referred to herein, is prevented by, is a breach of, or will result in a 

  
 Portions of
this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the
Securities Act of 1933, as amended. 

  
 6 

 CONFIDENTIAL TREATMENT REQUESTED 

 

	 	
breach of, any term, condition, or provision of any agreement or document to which it is now a party or by which it is bound; and 

 

	 	(f)	It shall furnish such satisfactory evidence regarding the representations and certifications described herein as may be required and requested by the INSTITUTE from time to time. 

Section 2.11 Reliance upon Representations. By awarding the Grant and executing this Contract, the INSTITUTE is relying, and will continue to rely
throughout the term of this Contract, upon the truthfulness, accuracy, and completeness of the RECIPIENT’s written assurances, certifications and representations. Moreover, the INSTITUTE would not have entered into this Contract with the
RECIPIENT but for such written assurances, certifications and representations. The RECIPIENT acknowledges that the INSTITUTE is relying upon such assurances, certifications and representations and acknowledges their materiality and significance.

 Section 2.12 Contingent upon Availability of Grant Funds. This Contract is contingent upon funding being available for the term of the
Contract and the RECIPIENT shall have no right of action against the INSTITUTE in the event that the INSTITUTE is unable to perform its obligations under this Contract as a result of the suspension, termination, withdrawal, or failure of funding to
the INSTITUTE or lack of sufficient funding of the INSTITUTE for this Contract. If funds become unavailable to the INSTITUTE during the term of the Contract, Section 8.01(c) shall apply. For the sake of clarity, and except as otherwise provided
by this Contract, if this Contract is not funded, then both parties are relieved of all of their obligations under this Contract. The INSTITUTE acknowledges and agrees that the Project is a multiyear project subject to Tex. Health & Safety
Code, Chr. 102, Section 102.257. 
 Section 2.13 Confidentiality of Documents and Information. In connection with work contemplated for
the Project or pursuant to complying with various provisions of this Contract, the RECIPIENT may disclose its confidential business, financial, technical, scientific information and other information to the INSTITUTE (“Confidential
Information”). To assist the INSTITUTE in identifying such information, the RECIPIENT shall mark or designate the information as “confidential,” provided however that the failure to so designate does not operate as a waiver to
protections provided by applicable law or this Contract. The INSTITUTE shall use no less than reasonable care to protect the confidentiality of the Confidential Information to the fullest extent permissible under the Texas Public Information Act,
Texas Government Code, Chapter 552 (the “TPIA”), and, except as otherwise provided in the TPIA to prevent the disclosure of the Confidential Information to third parties for a period of time equal to three (3) years from
the termination of the contract, unless the INSTITUTE and the RECIPIENT agree in writing to extend such time period, provided that this obligation shall not apply to information that: 

 

	 	(a)	was in the public domain at the time of disclosure or later became part of the public domain through no act or omission of the INSTITUTE in breach of this Contract; 

 

	 	(b)	was lawfully disclosed to the INSTITUTE by a third party having the right to disclose it without an obligation of confidentiality; 

  

	 	(c)	was already lawfully known to the INSTITUTE without an obligation of confidentiality at the time of disclosure; 

  

	 	(d)	 was independently developed by the INSTITUTE without using or referring to the RECIPIENT’s

  
 Portions of
this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the
Securities Act of 1933, as amended. 

  
 7 

 CONFIDENTIAL TREATMENT REQUESTED 

 

	 	
Confidential Information; or 

  

	 	(e)	is required by law or regulation to be disclosed. 

 The INSTITUTE shall hold the Confidential Information in
confidence, shall not use such Confidential Information except as provided by the terms of this Contract, and shall not disclose such Confidential Information to third parties without the prior written approval of the RECIPIENT or as otherwise
allowed by the terms of the Contract. Subject in all respects to the terms of this Contract and the TPIA, the INSTITUTE has the right to use and disclose the Confidential Information reasonably in connection with the exercise of its rights under the
Contract. 
 In the event that the INSTITUTE is requested or required (by oral questions, interrogatories, requests for information or documents in legal
proceedings, subpoena, civil investigative demand or other similar process by a court of competent jurisdiction or by any administrative, legislative, regulatory or self- regulatory authority or entity) to disclose any Confidential Information, the
INSTITUTE shall provide the RECIPIENT with prompt written notice of any such request or requirement so that the RECIPIENT may seek a protective order or other appropriate remedy. If, in the absence of a protective order or other remedy, the
INSTITUTE is nonetheless legally compelled to make any such disclosure of Confidential Information to any person, the INSTITUTE may, without liability hereunder, disclose only that portion of the Confidential Information that is legally required to
be disclosed, provided that the INSTITUTE will use reasonable efforts to assist the RECIPIENT, at the RECIPIENT’s expense, in obtaining an appropriate protective order or other reliable assurance that confidential treatment will be accorded the
Confidential Information. To the extent that such Confidential Information does not become part of the public domain by virtue of such disclosure, it shall remain Confidential Information hereunder. 

Article III 

DISBURSEMENT OF GRANT AWARD PROCEEDS 

Section 3.01 Payment of Grant Award Proceeds. The INSTITUTE will advance Grant award proceeds upon request by the RECIPIENT, consistent with the
amounts and schedule as provided in Attachment B. If the RECIPIENT does not request advancement of funds for some or the entire Grant award proceeds, disbursement of Grant award proceeds for services performed and allowable expenses and costs
incurred pursuant to the Scope of Work will be on a reimbursement basis. To the extent that completion of certain milestones is associated with a specific tranche of funding as reflected in the Scope of Work, those milestones shall be accomplished
before funding may be provided for next tranche of funding. The Institute reserves the right to terminate the Contract should a key milestone not be met. 

Section 3.02 Requests for Reimbursement and Quarterly Financial Status Reports. If the RECIPIENT does not elect to receive an advance disbursement
of Grant proceeds, the RECIPIENT’s requests for reimbursement shall be made on INSTITUTE Form 269a (Financial Status Report). If the RECIPIENT has elected to receive an advance disbursement of Grant proceeds, RECIPIENT shall submit INSTITUTE
Form 269a (Financial Status Report) to document all costs and allowable expenses paid with Grant proceeds. The RECIPIENT shall submit the INSTITUTE Form 269a quarterly to the INSTITUTE within 90 days following the end of the quarter covered by the
bill. A final INSTITUTE Form 269a shall be submitted by RECIPIENT not later than 90 days after the Termination Date. An extension of time for submission deadlines specified herein must be expressly authorized in writing by the INSTITUTE. 

  
 Portions of
this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the
Securities Act of 1933, as amended. 

  
 8 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 Section 3.03 Actual Costs and Allowable Expenses. Because the Approved budget for the Project(s)
as set forth in Attachment B is only an estimate, the parties agree that the RECIPIENT’s billings under this Contract will reflect the actual costs and expenses incurred in performing the Project(s), regardless of the Approved Budget, up to the
total contracted amount specified in Section 2.01 “Award of Monies.” The RECIPIENT shall use Grant proceeds only for allowable expenses consistent with state law and agency administrative rules. Allowable expenses for the Project(s)
shall be only as outlined in the Approved Budget and any modifications to same. 
 Section 3.04 Travel Expenses. Reimbursement for travel
expenditures shall be in accordance with the Approved Budget. Prior written approval from the INSTITUTE must be obtained before travel that exceeds the amount included in the Approved Budget commences. Failure to obtain such prior written approval
shall result in such excess travel costs constituting expenses that may not be taken into account for the purposes of calculating expenditure of Grant funds under this Contract. 

Section 3.05 Budget Modifications. The total Approved Budget and the assignment of costs may be adjusted based on implementation of the Scope of
Work, spending patterns, and unexpended funds, but only by an amendment to the Approved Budget. In no event shall an amendment to the Approved Budget result in payments in excess of the aggregate amount specified in Section 2.01 “Award of
Monies” or in approved supplemental funding for the Project, if any. The RECIPIENT may make transfers between or among lines within budget categories without prior written approval provided that: 

 

	 	(a)	The total dollar amount of all changes of any single line item within budget categories (individually and in the aggregate) is less than 10% of the total Approved Budget; 

 

	 	(b)	The transfer will not increase or decrease the total Approved Budget; 

  

	 	(c)	The transfer will not materially change the nature, performance level, or Scope of Work of the Project; and 

  

	 	(d)	The RECIPIENT submits a revised copy of the Approved Budget including a narrative justification of the changes prior to incurring costs in the new category. 

All other budget changes or transfers require the INSTITUTE’s express prior written approval. Transfer of funds between categories in the Project’s
Approved Budget may be allowed if requests are in writing, fit within the Scope of Work and the total Approved Budget, are beneficial to the achievement of the objectives of the Project, and appear to be an efficient, effective use of the
INSTITUTE’s funds. 
 Section 3.06 Withholding Payment. The INSTITUTE may withhold Grant award proceeds from the RECIPIENT if required
Financial Status Reports (Form 269a) are not on file for previous quarters or for the final period, if material program requirements are not met and remain uncured after a reasonable time period to cure, if the RECIPIENT is in breach of any material
term of this Contract, or in accordance with provisions of this Contract as well as applicable state or federal laws, regulations or administrative rules, and the breach remains uncured after a reasonable time period to cure. The INSTITUTE shall
have the right to withhold all or part of any future payments to the RECIPIENT to offset any prior advance payments made to the RECIPIENT for ineligible expenditures that have not been refunded to the INSTITUTE by the RECIPIENT 

  
 Portions of
this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the
Securities Act of 1933, as amended. 

  
 9 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 Section 3.07 Grant Funds as Supplement to Budget. The RECIPIENT shall use the Grant proceeds
awarded pursuant to this Contract to supplement its overall budget. These funds will in no event supplant existing funds currently available to the RECIPIENT that have been previously budgeted and set aside for the Project. The RECIPIENT will not
bill the INSTITUTE for any costs under this Contract that also have been billed or should have been billed to any other funding source. 

Section 3.08 Buy Texas. The RECIPIENT shall apply good faith efforts to purchase goods and services from suppliers in Texas to the extent
reasonably possible, to achieve a goal of more than 50 percent of such purchases from suppliers in Texas. 
 Section 3.09 Historically
Underutilized Businesses. The RECIPIENT shall use reasonable efforts to purchase materials, supplies or services from a Historically Underutilized Business (HUB). The Texas Procurement and Support Services website will assist in finding HUB
vendors (http://www.window.state.tx.us/procurement.) The RECIPIENT shall complete a HUB report with each annual report submitted to the INSTITUTE in accordance with Attachment E. 

Section 3.10 Limitation on Use of Grant Award Proceeds to Pay Indirect Costs. The RECIPIENT shall not spend more than five percent of the Grant
award proceeds for Indirect Costs. 
 Section 3.11 Carry Forward of Unspent Funds and No Cost Extension. RECIPIENT may request to carry forward
unspent funds into the budget for the next year. Carryover of unspent funds must be specifically approved by the INSTITUTE. The INSTITUTE may approve a no cost extension for the Contract for a period not to exceed six (6) months after the
Termination Date if additional time beyond the Termination date is required to ensure adequate completion of the approved project. The Contract must be in good fiscal and programmatic standing. All terms and conditions of the Contract shall continue
during any extension period and if such extension is approved, notwithstanding Section 2.03, all references to the “Termination Date” shall be deemed to mean the date of expiration of such extension period. 

Article IV 
 AUDITS AND
INSPECTIONS 
 Section 4.01 Record Keeping. The RECIPIENT, each Collaborator and each Contractor whose costs are funded in all or in part by
the Grant shall maintain or cause to be maintained books, records, documents and other evidence (electronic or otherwise) pertaining in any way to its performance under and compliance with the terms and conditions of this Contract
(“Records”). The RECIPIENT, each Collaborator and each Contractor shall use, or shall cause the entity which is maintaining such Records to use generally accepted accounting principles in the maintenance of such Records, and
shall retain or require to be retained all of such Records for a period of four (4) years from the Termination Date of the Contract. 

Section 4.02 Audits. Upon request and with reasonable notice, the RECIPIENT, each Collaborator and each Contractor whose costs are charged
to the Project shall allow, or shall cause the entity which is maintaining such items to allow, the INSTITUTE, or auditors working on behalf of the INSTITUTE, including the State Auditor and/or the Comptroller of Public Accounts for the State of
Texas, to review, inspect, audit, copy or abstract all of its Records during regular working hours. Acceptance of funds 

  
 Portions of
this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the
Securities Act of 1933, as amended. 

  
 10 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 
directly under the Contract or indirectly through a subcontract under the Contract constitutes acceptance of the authority of the INSTITUTE, or auditors working on behalf of the INSTITUTE,
including the State Auditor and/or the Comptroller of Public Accounts, to conduct an audit or investigation in connection with those funds for a period of four (4) years from the Termination Date of the Contract. 

Notwithstanding the foregoing, any RECIPIENT expending $500,000 or more in federal or state awards during its fiscal year shall obtain either an annual single
audit or a program specific audit. A RECIPIENT expending funds from only one federal program (as listed in the Catalog of Federal Domestic Assistance (CFDA) or one state program may elect to obtain a program specific audit in accordance with Office
of Management and Budget (OMB) Circular A-133 or with the State of Texas Uniform Grant Management Standards (UGMS). A single audit is required if funds from more than one federal or state program are spent by the RECIPIENT. The audited time period
is the RECIPIENT’s fiscal year, not the INSTITUTE funding period. 
 Section 4.03 Inspections. In addition to the audit rights specified in
Section 4.02 “Audits”, the INSTITUTE shall have the right to conduct periodic onsite inspections within normal working hours and on a day and a time mutually agreed to by the parties, to evaluate the Institute-Funded Activity. The
RECIPIENT shall fully participate and cooperate in any such evaluation efforts. 
 Section 4.04 On-going Obligation to Submit Requested
Information. The RECIPIENT shall, submit other information related to the Grant to the INSTITUTE as may be reasonably requested from time-to- time by the INSTITUTE, by the Legislature or by any other funding or regulatory bodies covering the
RECIPIENT’s activities under this Contract. 
 Section 4.05 Duty to Resolve Deficiencies. If an audit and/or inspection under this Article
IV finds there are deficiencies that should be remedied, then the RECIPIENT shall resolve and/or cure such deficiencies within a reasonable time frame specified by the INSTITUTE. Failure to do so shall constitute an Event of Default pursuant to
Section 8.03 “Event of Default.” Upon the RECIPIENT’S request, the parties agree to negotiate in good faith, specific extensions so that the RECIPIENT can cure such deficiencies. 

Section 4.06 Repayment of Grant Proceeds for Improper Use. In no event shall RECIPIENT retain Grant funds that have not been used by the RECIPIENT
for purposes for which the Grant was intended or in violation of the terms of this Contract. The RECIPIENT shall repay any portion of Grant proceeds used by the RECIPIENT for purposes for which the Grant was not intended, as determined by the final
results of an audit conducted pursuant to the provisions of this Contract. Unless otherwise expressly provided for in writing and appended to this Contract, the repayment shall be made to the INSTITUTE no later than forty-five (45) days upon a
written request by the INSTITUTE specifying the amount to be repaid and detailing the basis upon which such request is being made and the amount shall include interest calculated at an amount not to exceed five percent (5%) annually. The
RECIPIENT may request that the INSTITUTE waive the interest, subject in all cases to the INSTITUTE’S sole discretion. 
 Section 4.07 Repayment
of Grant Proceeds for Relocation Outside of Texas. The RECIPIENT shall repay the INSTITUTE all Grant proceeds disbursed to RECIPIENT in the event that RECIPIENT relocates its principal place of business outside of the State during the Contract
term or within 3 years after the final payment of the Grant funds is made by the INSTITUTE. 

  
 Portions of
this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the
Securities Act of 1933, as amended. 

  
 11 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 
Article V 
 ASSURANCES AND CERTIFICATIONS 

Adoption of Attachment C. The INSTITUTE and the RECIPIENT hereby adopt the terms of Attachment C in their entirety, incorporate them as if fully set
forth herein, and agree to perform and be bound by all such terms. 
 Article VI 

INTELLECTUAL PROPERTY AND REVENUE SHARING 

Adoption of Attachment D. The INSTITUTE and the RECIPIENT hereby adopt the terms of Attachment D in their entirety, incorporate them as if fully set
forth herein, and agree to perform and be bound by all such terms. 
 Article VII 

REPORTING 
 Adoption of Attachment E.
The INSTITUTE and the RECIPIENT hereby adopt the terms of Attachment E in their entirety, incorporate them as if fully set forth herein, and agree to perform and be bound by all such terms. 

Article VIII 
 EARLY
TERMINATION AND EVENT OF DEFAULT 
 Section 8.01 Early Termination of Contract. This Contract may be terminated prior to the Termination
Date specified in Section 2.03 “Contract Term” by: 
  

	 	(a)	Mutual written consent of all parties to this Contract; or 

  

	 	(b)	The INSTITUTE for an Event of Default (defined in Section 8.03) by the RECIPIENT; or 

  

	 	(c)	The INSTITUTE if allocated funds should become legally unavailable during the Contract period and the INSTITUTE is unable to obtain additional funds for such purposes; or 

 

	 	(d)	The RECIPIENT for convenience. 

 Section 8.02 Repayment of Grant Proceeds upon Early Termination.
The INSTITUTE may require the RECIPIENT to repay any unused portion of the disbursed Grant proceeds in the event of early termination under 8.01 (d) above or under Section 8.01(b) above, to the extent such Event of Default resulted
from Grant funds being expended in violation of this Contract. To the extent that the INSTITUTE exercises this option, the INSTITUTE shall provide written notice to the RECIPIENT stating the amount to be repaid, applicable interest calculated not to
exceed five percent (5%) annually, and the schedule for such repayment. The RECIPIENT may request that the INSTITUTE waive the interest, subject in all cases to the INSTITUTE’S sole discretion. In no event shall the RECIPIENT retain Grant
funds that have not been used by the RECIPIENT for purposes for which the Grant was intended. 
 Section 8.03 Event of Default. The
following events shall, unless expressly waived in writing by the INSTITUTE or fully cured by the RECIPIENT pursuant to the provisions herein, constitute an event of default (each, an “Event of Default”): 

  
 Portions of
this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the
Securities Act of 1933, as amended. 

  
 12 

 CONFIDENTIAL TREATMENT REQUESTED 

 

	 	(a)	The RECIPIENT’s failure, in any material respect, to conduct the Project in accordance with the approved Scope of Work and to demonstrate progress towards achieving the milestones set forth in Section 2.02;

  

	 	(b)	The RECIPIENT’s failure to conduct the Project within the State of Texas to the extent required under this Contract unless as otherwise specified in the application, Scope of Work or Approved Budget;

  

	 	(c)	The RECIPIENT’s failure to fully comply, in any material respect, with any provision, term, condition, covenant, representation, certification, or warranty contained in this Contract or any other document
incorporated herein by reference; 

  

	 	(d)	The RECIPIENT’s failure to comply with any applicable federal or state law, administrative rule, regulation or policy with regard to the conduct of the Project; 

 

	 	(e)	The RECIPIENT’s material misrepresentation or false covenant, representation, certification, or warranty made by the RECIPIENT herein, in the Grant application, or in any other document furnished by the RECIPIENT
pursuant to this Contract that was false or misleading at the time that it was made; or 

  

	 	(f)	The RECIPIENT ceases its business operations, has a receiver appointed for all or substantially all of its assets, makes a general assignment for the benefit of creditors, is declared insolvent by a court of competent
jurisdiction or becomes the subject, as a debtor, of a proceeding under the federal bankruptcy code, which such proceedings are not dismissed within ninety (90) days after filing. 

Section 8.04 Notice Required. If the RECIPIENT intends to terminate pursuant to Section 8.01(d) “Early Termination of Contract”, it
shall provide written notice to the INSTITUTE pursuant to the notice provisions of Section 9.21 “Notices” no later than thirty (30) days prior to the intended date of termination. 

If the INSTITUTE intends to terminate for an Event of Default under Section 8.01(b) by the RECIPIENT, as described in Section 8.03 “Event of
Default”, the INSTITUTE shall provide written notice to the RECIPIENT pursuant to Section 9.21 “Notices” and shall include a reasonable description of the Event of Default and, if applicable, the steps necessary to cure such
Event of Default. Upon receiving notice from the INSTITUTE, the RECIPIENT shall have thirty (30) days beginning on the day following the receipt of notice to cure the Event of Default. Upon request, the INSTITUTE may provide an extension of
time to cure the Event of Default(s) beyond the thirty (30) day period specified herein so long as the RECIPIENT is using reasonable efforts to cure and is making reasonable progress in curing such Event(s) of Default. The extension shall be in
writing and appended to the Contract. If the RECIPIENT is unable or fails to timely cure an Event of Default, unless expressly waived in writing by the INSTITUTE, this Contract shall immediately terminate as of the close of business on the final day
of the allotted cure period without any further notice or action by the INSTITUTE required. In addition, and notwithstanding the foregoing, the INSTITUTE and the RECIPIENT agree that certain events that cannot be cured shall, unless expressly
waived in writing by the INSTITUTE, constitute a final Event of Default under this Contract and this Contract shall terminate immediately upon the INSTITUTE giving the RECIPIENT written 

  
 Portions of
this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the
Securities Act of 1933, as amended. 

  
 13 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 
“Notice of Event of Default and FINAL TERMINATION.” 
 In the event that the
INSTITUTE terminates the Contract under Section 8.01(c) above because allocated funds become legally unavailable during the Contract period, the INSTITUTE shall immediately provide written notification to the RECIPIENT of such fact pursuant to
Section 9.21 “Notices.” The Contract is terminated upon the RECIPIENT’s receipt of that notification, subject to Section 9.09 “Survival of Terms.” 

Section 8.05 Duty to Report Event of Default. The RECIPIENT shall notify the INSTITUTE in writing pursuant to Section 9.21
“Notices”, promptly and in no event more than (30) days after it obtains knowledge of the occurrence of any Event of Default. The RECIPIENT shall include a statement setting forth reasonable details of each Event of Default and the
action which the RECIPIENT proposes to take with respect thereto. 
 Section 8.06 Obligations/Liabilities Affected by Early Termination. The
RECIPIENT shall not incur new obligations that otherwise would have been paid for using Grant funds after the receipt of notice as provided by Section 8.04 “Notice Required”, unless expressly permitted by the INSTITUTE in writing, and
shall cancel as many outstanding obligations as possible. The INSTITUTE shall not owe any fee, penalty or other amount for exercising its right to terminate the Contract in accordance with Section 8.01. In no event shall the INSTITUTE be liable
for any services performed, or costs or expenses incurred, after the Termination Date of the Contract. Early termination by either party shall not nullify obligations already incurred, including the RECIPIENT’s revenue sharing obligations as
set forth in Attachment D, or the performance or failure to perform obligations prior to the Termination Date. 
 Section 8.07 Interim Remedies.
Upon receipt by the RECIPIENT of a notice of Event of Default, and at any time thereafter until such Event of Default is cured to the satisfaction of the INSTITUTE or this Contract is terminated, the INSTITUTE may enforce any or all of the following
remedies (such rights and remedies being in addition to and not in lieu of any rights or remedies set forth herein): 
  

	 	(a)	The INSTITUTE may refrain from disbursing any amount of the Grant funds not previously disbursed; provided, however, the INSTITUTE may make such a disbursement after the occurrence of an Event of Default without thereby
waiving its rights and remedies hereunder; 

  

	 	(b)	The INSTITUTE may enforce any additional remedies it has in law or equity. 

 The rights and remedies herein
specified are cumulative and not exclusive of any rights or remedies that the INSTITUTE would otherwise possess. 
 Article IX 

MISCELLANEOUS 
 Section 9.01
Uniform Grant Management Standards. Unless otherwise provided herein, the RECIPIENT agrees that the Uniform Grant Management Standards (UGMS), developed by the Governor’s Budget and Planning Office as directed under the Uniform Grant
Management Act of 1981, TEX. GOVT. CODE, Ch. 783, apply as additional terms and conditions of this Contract and that the standards are adopted by reference in their entirety. If there is a conflict between the provisions of this Contract and UGMS,
the provisions of this Contract will prevail unless expressly stated otherwise. 
 Section 9.02 Management and Disposition of Equipment. During
the term of this Contract, the 

  
 Portions of
this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the
Securities Act of 1933, as amended. 

  
 14 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 
RECIPIENT may use Grant funds to purchase Equipment to be used for the authorized purpose of the Project, subject to the conditions set forth below. Unless otherwise provided herein, title to
Equipment shall vest in the RECIPIENT upon termination of the Contract. 
  

	 	(a)	The INSTITUTE must authorize the acquisition in advance and in writing but an acquisition is deemed authorized if included in the Approved Budget for the Project; 

 

	 	(b)	Equipment purchased with Grant funds must stay within the State of Texas; 

  

	 	(c)	Equipment purchased with Grant funds must be materially deployed to the uses and purposes related to the Project; 

  

	 	(d)	In the event the RECIPIENT is indemnified, reimbursed or otherwise compensated for any loss of, destruction of, or damage to the Equipment purchased using Grant funds, it shall use the proceeds to repair or replace said
Equipment; 

  

	 	(e)	Equipment may be exchanged (trade-in) or sold without the prior written approval of the INSTITUTE if the proceeds thereof shall be applied to the acquisition cost of replacement Equipment; 

 

	 	(f)	The RECIPIENT may use its own property management standards and procedures provided that it observes the terms of UGMS, A-102, in all material respects; 

 

	 	(g)	The title or ownership of the Equipment shall not be encumbered for purposes other than the Project nor or transferred other than to a permitted assignee of this Contract without the prior written approval of the
INSTITUTE; 

  

	 	(h)	If the original or replacement Equipment is no longer needed for the originally authorized purpose or for other activities supported by the INSTITUTE, the RECIPIENT shall request disposition instructions from the
INSTITUTE and, upon receipt, shall fully comply therewith; and 

  

	 	(i)	If this Contract is terminated early pursuant to Section 8.01(b),(d), (e) or (f) above, the INSTITUTE shall determine the final disposition of Equipment purchased with Grant award money.

 Section 9.03 Supplies and Other Expendable Property. The RECIPIENT shall classify as materials, supplies and other expendable
property the allowable unit acquisition cost of such property under $5,000 necessary to carry out the Project. Title to supplies and other expendable property shall vest in the RECIPIENT upon acquisition. 

Section 9.04 Acknowledgement of Grant Funding and Publicity. The parties agree to the following terms and conditions regarding acknowledging Grant
funding and publicity: 
  

	 	(a)	The parties agree to fully cooperate and coordinate with each other in connection with all press releases and publications regarding the award of the Grant, the execution of the Contract and the Institute-Funded
Activities. 

  
 Portions of
this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the
Securities Act of 1933, as amended. 

  
 15 

 CONFIDENTIAL TREATMENT REQUESTED 

 

	 	(b)	The RECIPIENT shall notify the INSTITUTE’s Information Specialist or similar personnel at least three business days prior to any press releases, advertising, publicity, use of CPRIT logo, or other promotional
activities that pertain to the Project or any Institute-Funded Activity. In the event that the INSTITUTE wishes to participate in a joint press release, the RECIPIENT shall coordinate and cooperate with the INSTITUTE’s Information Specialist or
similar personnel to develop a mutually agreeable joint press release. 

  

	 	(c)	Consistent with the goal of encouraging development of scientific breakthroughs and dissemination of knowledge, publication or presentation of scholarly materials is expected and encouraged. The RECIPIENT may publish in
scholarly journals or other peer-reviewed journals (including graduate theses and dissertations) and may make presentations at scientific meetings without prior notice to or consent of the INSTITUTE, except as may otherwise be set forth in this
Contract. The RECIPIENT shall promptly notify the INSTITUTE when any scholarly presentations or publications have been accepted for public disclosure and shall provide the INSTITUTE with final copies of all such accepted presentations and
publications. The RECIPIENT shall acknowledge receipt of the INSTITUTE funding in all publications, presentations, press releases and other materials regarding the work associated with the Institute-Funded Activities. The RECIPIENT shall promptly
submit an electronic version of all published manuscripts to PubMed Central in accordance with Section 9.05 “Public Access to Research Results.” 

  

	 	(d)	When grant funds are used to prepare print or visual materials for educational or promotional purposes for the general public (e.g., patients), and excluding presentations and publications discussed above in subsection
(c), the RECIPIENT shall provide a copy of such materials to the INSTITUTE at least ten (10) days prior to printing. The RECIPIENT shall also acknowledge receipt of the INSTITUTE funding on all such materials including, but not limited to,
brochures, pamphlets, booklets, training fliers, project websites, videos and DVDs, manuals and reports, as well as on the labels and cases for audiovisual or videotape/DVD presentations. 

Section 9.05 Public Access to Results of Institute-Funded Activities. The RECIPIENT shall submit an electronic version of its final peer-reviewed
journal manuscripts that arise from Grant funds to the digital archive National Library of Medicine’s PubMed Central upon acceptance for publication. These papers must be accessible to the public on PubMed no later than 12 months after
publication. This policy is subject to the terms of Attachment D and does not supplant applicable copyright law. For clarity, this policy is not intended to require the RECIPIENT to make a disclosure at a time or in any manner that would cause the
RECIPIENT to abandon, waive or disclaim any intellectual property rights that it is obligated to protect pursuant to the terms of Attachment D. 

Section 9.06 Work to be Conducted in State. The RECIPIENT agrees that it will use reasonable efforts to direct that any new or expanded
preclinical testing, clinical trials, commercialization or manufacturing that is part of or relating to any Institute-Funded Activities take place in the State of Texas, including the establishment of facilities to meet this purpose. If the
RECIPIENT decides not to conduct such work in the State of Texas, the RECIPIENT shall provide a prior written explanation to the INSTITUTE detailing the RECIPIENT’s reasons for conducting the work outside of the State of Texas and the
RECIPIENT’s efforts made to conduct the work in the State of Texas 
 Section 9.07 Duty to Notify. During the term of this Contract
and for a period of five (5) years thereafter, the RECIPIENT is under a continuing obligation to notify the INSTITUTE’s executive director at 

  
 Portions of
this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the
Securities Act of 1933, as amended. 

  
 16 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 
the same time it is required to notify any Federal or State entity of any unexpected adverse event or condition that materially impacts the performance or general public perception of the conduct
or results of the Project and the Institute-Funded Activities, including any impact to the Scope of Work included in the Contract and events or results that have a serious adverse impact on human health, safety or welfare. By way of example only, if
clinical testing of the results of the Institute-Funded Activities reveal an unexpected risk of developing serious health conditions or death, then the RECIPIENT shall, at the same time it notifies any Federal or State entity, promptly so notify the
INSTITUTE’s executive director even if such results are not available until after the term of this Contract. Notice required under this section shall be made as promptly as reasonably possible and shall follow the procedures set forth in
Section 9.21 “Notices.” 
 Section 9.08 Severability. If any provision of this Contract is construed to be invalid, illegal or
unenforceable in any respect, such invalidity, illegality or enforceability shall not affect any other provisions hereof. The invalid, illegal or unenforceable provision shall be deemed stricken and deleted to the same extent and effect as if never
incorporated herein. All other provisions shall continue as provided in this Contract. 
 Section 9.09 Survival of Terms. Termination or
expiration of this Contract for any reason will not release either party from any liabilities or obligations set forth in this Contract that: (1) the Parties have expressly agreed shall survive any such termination or expiration; or
(2) remain to be performed or by their nature would be intended to be applicable following any such termination or expiration. Such surviving terms include, but are not limited to, Sections 2.13, 4.01, 4.02, 4.05, 4.06, 8.02, 8.06, 9.04, 9.05,
9.06, 9.07, 9.09, 9.14, 9.15, 9.16, 9.17, 9.18, and Attachment D. 
 Section 9.10 Binding Effect and Assignment or Modification. This Contract
and all terms, provisions and obligations set forth herein shall be binding upon and shall inure to the benefit of the parties and their successors and permitted assigns, including all other state agencies and any other agencies, departments,
divisions, governmental entities, public corporations or other entities which shall be successors to either of the parties or which shall succeed to or become obligated to perform or become bound by any of the covenants, agreements or obligations
hereunder of either of the parties hereto. Upon a permitted assignment of this Contract by RECIPIENT, all references to “the RECIPIENT” herein shall be deemed to refer to such permitted assignee. 

Section 9.11 No Waiver of Contract Terms. Neither the failure by the RECIPIENT or the INSTITUTE, in any one or more instances, to insist upon the
complete and total observance or performance of any term or provision hereof, nor the failure of the RECIPIENT or the INSTITUTE to exercise any right, privilege or remedy conferred hereunder or afforded by law, shall be construed as waiving any
breach of such term or provision or the right to exercise such right, privilege or remedy thereafter. In addition, no delay on the part of either the RECIPIENT or the INSTITUTE, in exercising any right or remedy hereunder shall operate as a waiver
thereof, nor shall any single or partial exercise of any right or remedy preclude other or further exercise thereof or the exercise of any other right or remedy. 

Section 9.12 No Waiver of Sovereign Immunity. No provision of this Contract is in any way intended to constitute a waiver by the INSTITUTE, the
RECIPIENT (if applicable), or the State of Texas of any immunities from suit or from liability that the INSTITUTE, the RECIPIENT, or the State of Texas may have by operation of law. 

  
 Portions of
this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the
Securities Act of 1933, as amended. 

  
 17 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 Section 9.13 Force Majeure. Neither the INSTITUTE nor the RECIPIENT will be liable for any
failure or delay in performing its obligations under the Contract if such failure or delay is due to any cause beyond the reasonable control of such party, including, but not limited to, unusually severe weather, strikes, natural disasters, fire,
civil disturbance, epidemic, war, court order or acts of God. The existence of such causes of delay or failure will extend the period of performance in the exercise of reasonable diligence until after the causes of delay or failure have been
removed. Each party must inform the other in accordance with Section 9.21 “Notices” within five (5) business days, or as soon as it is practical, of the existence of a force majeure event or otherwise waive this right as a
defense. 
 Section 9.14 Disclaimer of Damages. IN NO EVENT WILL EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR ANY INDIRECT, SPECIAL,
PUNITIVE, EXEMPLARY, INCIDENTAL OR CONSEQUENTIAL DAMAGES. THIS LIMITATION WILL APPLY REGARDLESS OF WHETHER OR NOT THE OTHER PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. 

Section 9.15 Indemnification and Hold Harmless. Except as provided herein, the RECIPIENT agrees to fully indemnify and hold the INSTITUTE and the
State of Texas harmless from and against any and all claims, demands, costs, expenses, liabilities, causes of action and damages of every kind and character (including reasonable attorneys fees) which may be asserted by any third party in any way
related or incident to, arising out of, or in connection with (1) the RECIPIENT’s negligent, intentional or wrongful performance or failure to perform under this Contract, (2) the RECIPIENT’s receipt or use of Grant funds, or
(3) any negligent, intentional or wrongful act or omission committed by the RECIPIENT as part of an Institute-Funded Activity or during the Project. In addition, the RECIPIENT agrees to fully indemnify and hold the INSTITUTE and the State of
Texas harmless from and against any and all costs and expenses of every kind and character (including reasonable attorneys fees, costs of court and expert fees) that are incurred by the INSTITUTE or the State of Texas arising out of or related to a
third party claim of the type specified in the preceding sentence. Notwithstanding the preceding, such indemnification shall not apply in the event of the sole or gross negligence of the INSTITUTE. If the RECIPIENT is a State of Texas agency or
institution of higher education, then this Section 9.15 is subject to the extent authorized by the Texas Constitution and the laws of the State of Texas. 

The RECIPIENT acknowledges and agrees that this indemnification shall apply to, but is not limited to, employment matters, taxes, personal injury, and
negligence. 
 It is understood and agreed that it is not the intent of the parties to expand or increase the liability of the State of Texas under this
Article. This provision is intended to prevent the RECIPIENT, the INSTITUTE and the State of Texas from attempting or appearing to assume liability it does not have the statutory or legal power to assume. 

Section 9.16 Alternative Dispute Resolution. If applicable, the dispute resolution process provided for in TEX. GOVT. CODE, Ch. 2260 shall be
used, as further described herein, to resolve any claim for breach of contract made against the INSTITUTE (excluding any uncured Event of Default). The submission, processing and resolution of a party’s claim are governed by the published rules
adopted by the Attorney General pursuant to TEX. GOVT. CODE, Ch. 2260, as currently effective, hereafter enacted or subsequently amended. 

Section 9.17 Applicable Law and Venue. This Contract shall be construed and all disputes shall be considered in accordance with the laws of the
State of Texas, without regard to its principles governing 

  
 Portions of
this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the
Securities Act of 1933, as amended. 

  
 18 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 
the conflict of laws. Provided that the RECIPIENT first complies with procedures set forth in Section 9.16 “Alternative Dispute Resolution,” exclusive venue and jurisdiction for
the resolution of claims arising from or related to this Contract shall be in the federal and state courts in Travis County, Texas. 
 Section 9.18
Attorneys’ Fees. In the event of any litigation, appeal or other legal action to enforce any provision of the Contract, the RECIPIENT shall pay all expenses of such action, including attorneys’ fees and costs, if the INSTITUTE is the
prevailing party. If the RECIPIENT is a State of Texas agency or institution of higher education, then this Section 9.18 is subject to the extent authorized by the Texas Constitution and the laws of the State of Texas. 

Section 9.19 Counterparts. This Contract may be executed in any number of counterparts, each of which when so executed and delivered shall be an
original, but such counterparts shall together constitute one and the same instrument. 
 Section 9.20 Construction of Terms. The
headings used in this Contract are inserted only as a matter of convenience and for reference and shall not affect the construction or interpretation of this Contract. Where context so indicates, a word in the singular form shall include the plural,
a word in the masculine form the feminine, and vice-versa. The word “including” and similar constructions (such as “includes”, “included”, “for example”, “such as”, and “e.g.”) shall mean
“including, without limitation” throughout this Contract. The words “and” and “or” are not intended to convey exclusivity or nonexclusivity except where expressly indicated or where the context so indicates in order to
give effect to the intent of the parties. 
 Section 9.21 Notices. All notices, requests, demands and other communications will be in
writing and will be deemed given on the date received as demonstrated by (i) a courier’s receipt or registered or certified mail return receipt signed by the party to whom such notice was sent, provided that such notice was sent to the
address provided in the signature block of this Contract, or (ii) a fax confirmation page showing that such fax was successfully transmitted to the fax number provided in the signature block of this Contract. Notices shall be sent to the
parties at the addresses or fax numbers specified herein or as may be updated from time to time by the applicable party in a writing delivered to the other party pursuant to the terms of this Section. 

  
 Portions of
this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the
Securities Act of 1933, as amended. 

  
 19 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 

 
 ATTACHMENT A 

Project Description Summary 
  

			
	 Key Gating

Milestone
	  	 Use of Proceeds During Funding
Period

	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]

  
 Portions of
this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the
Securities Act of 1933, as amended. 

  

 CONFIDENTIAL TREATMENT REQUESTED 

 

 Project Goals and Timelines 

[***] 

  
 Portions of
this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the
Securities Act of 1933, as amended. 

  

 CONFIDENTIAL TREATMENT REQUESTED 

 

 

             
 Application
ID:                  CC121020 

Principal Investigator/Program Director: Eric
Poma                   
 ATTACHMENT B

 Detailed Budget Form 
  

													
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  		  		  		  		  		  	[***]
	[***]	  		  		  		  		  		  	[***]
	[***]	  		  		  		  		  		  	[***]
	[***]	  		  		  		  		  		  	[***]
	[***]	  	[***]	  	[***]	  		  		  		  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  		  		  	[***]
	[***]	  		  		  	  		  		  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  		  		  		  		  		  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
						
	[***]	  	[***]	  		  		  		  	
	[***]	  	[***]	  		  		  		  	
	[***]	  	[***]	  		  		  		  	
	[***]	  	[***]	  		  		  		  	
	[***]	  	[***]	  		  		  		  	
	[***]	  	[***]	  		  		  		  	
	[***]	  	[***]	  		  		  		  	

 For questions regarding this form, please contact Alfonso Royal at (512) 305-8488 or aroyal@cprit.state.tx.us. 

Rev 4/6/2011 

  
 Portions of
this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the
Securities Act of 1933, as amended. 

  

 CONFIDENTIAL TREATMENT REQUESTED 

 

 

 
 ATTACHMENT C 

ASSURANCES AND CERTIFICATIONS 

This Attachment C is hereby incorporated into and made a part of that certain CANCER RESEARCH GRANT CONTRACT
(“Contract”) by and between the Cancer Prevention and Research Institute of Texas (“CPRIT” or the “INSTITUTE”) and the RECIPIENT. A capitalized term used in this Attachment
shall have the meaning given to term in the Contract or in the Attachments to the Contract, unless otherwise defined herein. In the event of a conflict between the provisions of this Attachment and the provisions of the Contract, this Attachment
shall control. Notwithstanding any other provision of this Attachment C, each reference to “compliance” in the foregoing certifications and assurances shall mean “compliance in all material respects” and the RECIPENT shall be
deemed to be in compliance with a law, regulation or policy identified in a particular certification or assurance specified in this Attachment C if the RECIPIENT is in compliance in all materials respects with such law, regulation or policy, as
applicable. 
 By signing this Contract, RECIPIENT certifies compliance with the following assurances and certifications required by the
INSTITUTE (listed below). RECIPIENT further acknowledges that its obligations pursuant to the following assurances and certifications are ongoing. 

Section C1.01 Demonstration of Matching Funds. Pursuant to TEX. HEALTH & SAFETY CODE § 102.255(d) and T.A.C. § 703.11, RECIPIENT has
an amount of funds equal to one-half of the amount of the Grant to be disbursed each fiscal year of the Contract term dedicated to the same area of cancer research that is the subject of the Grant as demonstrated by the form incorporated herein to
Attachment C. The RECIPIENT shall update the matching funds certification annually for each fiscal year that Grant funds are disbursed. The update must be on or before the anniversary of the Effective Date. 

Section C1.02 Payment of Taxes. RECIPIENT‘s payment of franchise taxes is current or, if the RECIPIENT is exempt from payment of franchise taxes,
that it is not subject to the State of Texas franchise tax. If franchise tax payments become delinquent during the Contract term, payments under this Contract may, upon delivery of written notice by the INSTITUTE to the RECIPIENT be withheld until
the RECIPIENT’s delinquent franchise tax is paid in full. The RECIPIENT also acknowledges that it is not otherwise exempt from state sales or occupancy tax as a result of this Contract. 

Section C1.03 Compliance with Confidentiality Guidelines Relating to Personal and Medical Information. RECIPIENT complies with all applicable laws,
rules and regulations relating to personal and medical information. Without in any way limiting the foregoing, RECIPIENT maintains and enforces, to the extent applicable to RECIPIENT, appropriate facility and information technology access rules and
procedures to protect against inappropriate disclosure of patient records and all other documents containing patient personal and medical information deemed confidential by law, which are maintained in connection with the Project and
Institute-Funded Activities, including provisions that comply with the requirements of the INSTITUTE’s rules, 25 T.A.C. Section 703.14. Upon request from the INSTITUTE, RECIPIENT will timely furnish a copy of the RECIPIENT’s facility
and information technology access rules and procedures, as well as any other applicable confidentiality guidelines. 
 If RECIPIENT, including any
Collaborators or Contractors, works directly with patients or otherwise has access to or maintains patient personal and medical information, RECIPIENT specifically addresses Health Insurance Portability and Accountability Act of 1996 regulations
concerning confidentiality of personal and medical information. Any disclosure of patient confidential information in any way related 

  
 Portions of
this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the
Securities Act of 1933, as amended. 

  
 Page C1 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 to the Project (including information that may be required by reports and inspections) must be in accordance
with all applicable laws. 
 Section C1.04 Conduct of Research or Service Provided. RECIPIENT understands that the Project must be conducted with
full consideration for the ethical and medical implications of the research performed or services delivered and comply with all applicable federal and state laws regarding the conduct of the research or service. 

Section C1.05 Regulatory Certificates, Licenses and Permits. All of the RECIPIENT’s personnel, facilities and equipment involved or to be involved
in the Project are certified, licensed, permitted, registered or approved by the appropriate regulating agency, where applicable. Any revocation, surrender, expiration, non-renewal, inactivation or suspension of any such certification, license,
permit, registration or approval shall constitute grounds for Contract termination if the same is not remedied (or alternative personnel, facilities and/or equipment identified, as applicable, for use in the Project) within the applicable cure
period specified in Section 8.04. 
 Section C1.06 Assurances and Certifications in Accordance with the NIH Grants Policy
Statement: 
  

	 	(a)	Civil Rights. Compliance with Title VI of the Civil Rights Act of 1964. 

  

	 	(b)	Handicapped Individuals. Compliance with Section 504 of the Rehabilitation Act of 1973 as amended. 

  

	 	(c)	Sex Discrimination. Compliance with Section 901 of Title IX of the Education Amendments of 1972 as amended. 

  

	 	(d)	Age Discrimination. Compliance with the Age Discrimination Act of 1975, as amended. 

  

	 	(e)	Patents, Licenses and Inventions. Compliance with the Standard Patent Rights clauses as specified in 37 CFR, Part 401 or 35 U.S.C. 203, if appropriate and applicable, in a manner that adequately protects the
INSTITUTE’S rights in the Project Results. 

  

	 	(f)	Human Subjects. Compliance with the requirements of federal policy concerning the safeguarding of the rights and welfare of human subjects who are involved in activities supported by federal funds. Before any
funding may be utilized for any portion of the Project involving human subjects, RECIPIENT must receive approval from RECIPIENT’s Institutional Review Board (IRB). Upon request, a copy of RECIPIENT’s IRB approval must be provided to the
INSTITUTE. 

  

	 	(g)	Human Biological/Anatomical Material. Compliance with the recommendations of the NIH Office of Human Subject Research Medical Administrative Series (MAS) #MO1-2 entitled “Procurement and Use of Human
Biological Materials for Research,” and any other applicable federal or state requirements pertaining to the procurement and use of human biological material for research. 

 

	 	(h)	 Use of Animals. Compliance with applicable portions of the Animal Welfare Act (PL 89-544 as amended) and
appropriate Public Health Service Policy on Humane Care and Use of 

  
 Portions of
this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the
Securities Act of 1933, as amended. 

  
 Page C2 

 CONFIDENTIAL TREATMENT REQUESTED 

 

	 	
Laboratory Animals regulations. Before any funding may be utilized for any portion of the Project involving animal subjects, RECIPIENT must receive approval from RECIPIENT’s Institutional
Animal Care and Use Committee (IACUC). Upon request, a copy of RECIPIENT’s IACUC approval must be provided to the INSTITUTE. 

  

	 	(i)	Debarment and Suspension. RECIPIENT certifies that neither it nor the Principal Investigator/Project Director or any other Recipient Personnel or personnel of any Collaborator or Contractor assigned to work on
the Project are debarred, suspended, proposed for debarment, declared ineligible or otherwise excluded from participation in the Project by any federal or state department or agency. 

 

	 	(j)	Non-Delinquency on Federal or State Debt. RECIPIENT certifies that neither it, nor, to its knowledge, any person to be paid from funds under this Contract, is delinquent in repaying any Federal debt as defined by
OMB Circular A-129 or any debt to the State of Texas. 

  

	 	(k)	Eligibility to Receive Payments on State Contracts. RECIPIENT certifies that it and, to its knowledge, the Principal Investigator/Project Director are not ineligible to receive the Grant award under this Contract
pursuant to Tex. Fam. Code Ann. Section 231.006 and acknowledges that this Contract may be terminated and payment may be withheld if this certification is inaccurate. 

 

	 	(l)	Drug-Free Workplace. Compliance with the Drug-Free Workplace Act of 1988 (45 CFR 82). 

  

	 	(m)	Misconduct in Science. Compliance with 42 CFR Part 50, Subpart A, and Final Rule as published at 54 CFR 32446, August 8, 1989. 

 

	 	(n)	Objectivity of Research/Conflict of Interest. Compliance with the NIH requirement to maintain a written standard of conduct and comply with 42 CFR Part 50, Subpart F, Responsibility of Applicants for Promoting
Objectivity in Research. RECIPIENT must notify the INSTITUTE of any conflicting financial interests pertaining to the performance of the Project and assure that such conflict of interest has been appropriately managed, reduced or eliminated.

  

	 	(o)	Trafficking in Persons. Compliance with the NIH regulations on trafficking in persons as published at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-08-055.html. 

 

	 	(p)	Criminal Misconduct. RECIPIENT shall promptly report to the INSTITUTE issues involving potential civil or criminal fraud related in any way to the Project, the Institute-Funded Activity or this Contract, such as
false claims or misappropriation of federal or state funds. 

  
 Portions of
this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the
Securities Act of 1933, as amended. 

  
 Page C3 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 

 
 ATTACHMENT C 

CPRIT Matching Requirement Certification Form 
  

					
	FOR:    	  	Entity/Institution Name:	 	Molecular Templates, Inc. (Total CPRIT Awards shown represent 56.18% of the year 1 budget)
		  	Project Number(s):	 	CC121020

  

																																																													
	 	 	Award Year #1	 	 	Award Year #2	 	 	Award Year #3	 	 	Award Year #4	 	 	Award Year #5	 
	 	 	Total
CPRIT
Awards	 	 	Entity’s/
Institution’s
Dedicated
Funds	 	 	Actual
“Non
CPRIT”
Funds
Expended	 	 	Total
CPRIT
Awards	 	 	Entity’s/
Institution’s
Dedicated
Funds	 	 	Actual
“Non
CPRIT”
Funds
Expended	 	 	Total
CPRIT
Awards	 	 	Entity’s/
Institution’s
Dedicated
Funds	 	 	Actual
“Non
CPRIT”
Funds
Expended	 	 	Total
CPRIT
Awards	 	 	Entity’s/
Institution’s
Dedicated
Funds	 	 	Actual
“Non
CPRIT”
Funds
Expended	 	 	Total
CPRIT
Awards	 	 	Entity’s/
Institution’s
Dedicated
Funds	 	 	Actual
“Non
CPRIT”
Funds
Expended	 
	For purposes of the certification use the following research categories to classify encumbered funds that are dedicated to cancer research:	 				 				 				 				 				 				 				 				 				 				 				 				 				 				 			
	(1) Cancer biology and genetics, including oncogenesis and collection and characterization of tumors (genomics, proteomics, other “omics”);	 				 				 				 				 				 				 				 				 				 				 				 				 				 				 			
	(2) Cancer immunology, including vaccines;	 				 				 				 				 				 				 				 				 				 				 				 				 				 				 			
	(3) Cancer imaging and diagnostics;	 				 				 				 				 				 				 				 				 				 				 				 				 				 				 			
	(4) Cancer epidemiology and outcomes research; and	 				 				 				 				 				 				 				 				 				 				 				 				 				 				 			
	(5) Cancer treatment, including drug discovery and development and clinical trials.	 	 	[	***] 	 	 	[	***] 	 				 				 				 				 				 				 				 				 				 				 				 				 			
	Total	 	 	[	***] 	 	 	[	***] 	 	$	0.00	 	 	$	0.00	 	 	$	0.00	 	 	$	0.00	 	 	$	0.00	 	 	$	0.00	 	 	$	0.00	 	 	$	0.00	 	 	$	0.00	 	 	$	0.00	 	 	$	0.00	 	 	$	0.00	 	 	$	0.00	 
	Total non-state funds leveraged as a match for award.	 	 				 				 				 				 				 				 	$		 	 				 				 	$		 	 				 				 	$		 	 			

 The information above is the entity/Institution’s demonstration of encumbered available funds
pursuant to its certification in Attachment C. 
 This certification is on an annual basis and can be made on an entity/institutional level or
project by project. The entity/institutional level requires the match to reflect all research grant awards received by the entity/institution, including any FY2010 CPRIT research awards. 

To clarify, encumbered funds may include but are not necessarily limited to: (1) Federal funds (including American Recovery and Reinvestment Act of 2009
funds, and the fair market value of drug development support provided to the recipient by the National Cancer Institute (NCI) or other similar programs); (2) State of Texas funds (Non-CPRIT); (3) Other States’ funds;
(4) Non-governmental funds (including private funds, foundation grants, gifts and donations); and (5) Unrecovered indirect costs not to exceed 10 percent of the grant award amount, subject to the following conditions: (A) These costs
are not otherwise charged against the grant as the five percent indirect funds (B) The Institution or recipient must have a documented federal indirect cost rate or an indirect cost rate certified by an independent accounting firm; and
(C) The allowance for unrecovered indirect costs must be specifically approved by the Executive Director. 
 The following items do not qualify as
encumbered funds: 
 (1) In-kind costs; (2) Volunteer services furnished to the grant recipient; (3) Noncash contributions; (4) Income earned
not available at the time of award; (5) Pre-existing real estate including building, facilities and land; (6) Deferred giving such as a charitable remainder annuity trust, a charitable remainder unitrust, or a pooled income fund; or
(7) Other items as may be determined by the Oversight Committee. 
 For questions regarding this form, please contact Alfonso Royal
at (512) 305-8488 or by email at aroyal@cprit.state.tx.us 
 Rev 5/17/2011 

  
 Portions of
this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the
Securities Act of 1933, as amended. 

  

 CONFIDENTIAL TREATMENT REQUESTED 

 

 

 
 ATTACHMENT D 

INTELLECTUAL PROPERTY AND REVENUE SHARING 

This Attachment D is hereby incorporated into and made a part of that certain CANCER RESEARCH GRANT CONTRACT
(“Contract”) by and between the Cancer Prevention and Research Institute of Texas (“CPRIT” or the “INSTITUTE”) and the RECIPIENT. A capitalized term used in this Attachment
shall have the meaning given the term in the Contract or in the Attachments to the Contract, unless otherwise defined herein. In the event of a conflict between the provisions of this Attachment and the provisions of the Contract, this Attachment
shall control. 
 PART 1 

OWNERSHIP AND INTELLECTUAL PROPERTY PROTECTION 

Section D1.01 Ownership of Project Results. RECIPIENT and its Collaborators shall retain ownership of the Institute-Funded Technology and the
Institute-Funded IPR, subject to the terms of the Contract. 
 Section D1.02 Transfer or Assignment of Rights to a Third Party. RECIPIENT shall
notify the INSTITUTE of any proposed transfer or assignment of rights in any Institute-Funded IPR to a third party. RECIPIENT shall ensure that, in any assignment or transfer of Institute-Funded IPR, the transferee or assignee agrees in writing to
(i) recognize that the Institute-Funded IPR is transferred or assigned subject to the licenses, interests and other rights in such Institute-Funded IPR provided to the INSTITUTE in the Contract and any applicable law or regulation, and
(ii) take all actions commercially reasonable to protect all such licenses, interests and other rights. 
 Section D1.03 Protection of
Institute-Funded IPR. Subject to Section D5.01RECIPIENT shall use commercially reasonable efforts to appropriately protect the Institute-Funded IPR, including without limitation, diligently seeking registration of patents and copyrights covering
the Institute-Funded Technology, as appropriate. If RECIPIENT elects to abandon Institute-Funded IPR (including any partial abandonment of Institute-Funded IPR in specific territories), RECIPIENT shall provide the INSTITUTE with prior written notice
of such election, with sufficient time (but no less than 30 days) for the INSTITUTE to exercise its rights in Section D5.01 in relation to the subject Institute-Funded IPR. 

Section D1.04 Cost of Protection. The INSTITUTE shall not be responsible for, and no Grant funds may be used to pay for, any costs or expenses
associated with RECIPIENT’s efforts to protect the Institute- Funded IPR. 
 Section D1.05 Inventions. 

(a) Disclosures. RECIPIENT shall notify INSTITUTE of each Institute-Funded Invention by delivering a copy of the invention disclosure
form (or similar document) within thirty (30) days after RECIPIENT receives the form from its Inventor. In the event that the invention disclosure form is revised or updated, RECIPIENT shall provide the INSTITUTE with the revised/updated
invention disclosure form as part of the RECIPIENT’s annual written report. 
 (b) Patent Prosecution and Maintenance. For all
Institute-Funded Inventions for which patent protection is pursued, RECIPIENT shall provide an annual written report to the INSTITUTE regarding the status of pending applications and issued patents. 

Section D1.06 Required Agreements with RECIPIENT Personnel and Contractors. The RECIPIENT shall have, maintain and enforce written policies or
agreements applicable to RECIPIENT Personnel and 

  
 Portions of
this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the
Securities Act of 1933, as amended. 

  
 Page D1 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 
Contractors with terms sufficient to enable RECIPIENT to fully comply with all terms and conditions of this Contract. RECIPIENT shall promptly report to INSTITUTE any material breach of such
policies or agreements relating to or affecting any of the material provisions of this Contract. 
 Section D1.07 Agreements with Collaborators. All
agreements between RECIPIENT and a Collaborator relating to or affecting joint ownership of any Project Result shall recognize the licenses, interests and other rights provided to the INSTITUTE in the Contract. RECIPIENT shall provide to the
INSTITUTE a copy of each such agreement affecting joint ownership of any Project Result. 
 PART 2 

NON-COMMERCIAL LICENSES 
 Section
D2.01 RECIPIENT License. In granting an Exclusive License to any Project Result, RECIPIENT shall retain the right to Exploit all Project Results (including material embodiments thereof) for education, research and other non-commercial purposes,
and the right to grant the licenses pursuant to Section D2.02 below. 
 Section D2.02 INSTITUTE License. RECIPIENT agrees to grant, and does
hereby grant, to the INSTITUTE a non-exclusive, irrevocable, royalty-free, perpetual, worldwide license under the Institute-Funded IPR to Exploit all Project Results (including material embodiments thereof) for or on behalf of the INSTITUTE and
other governmental entities and agencies of the State of Texas for education, research and other non-commercial purposes only. RECIPIENT shall make the Institute-Funded Technology available by reasonable means to the INSTITUTE in order for the
INSTITUTE to exercise its rights under this Section. The INSTITUTE may not transfer or sublicense the licenses granted under this Section, except to the State of Texas or other Texas agency. Without the prior written consent of RECIPIENT, INSTITUTE
shall not publish or permit to be published any information which RECIPIENT reasonably deems to be RECIPIENT’s Confidential Information. When publishing, INSTITUTE shall appropriately acknowledge RECIPIENT’s financial support of the
Institute-Funded IPR. Furthermore, Institute agrees that any sublicense granted under this Section to other governmental entities or agencies of the State of Texas shall include a similar obligation with respect to publication review. 

Section D2.03 No Implied Licenses. No implied licenses are granted under this Agreement including any license to any Intellectual Property Rights owned
or controlled by RECIPIENT outside of the Institute- Funded IPR. Nothing in this Agreement shall be construed to impose an obligation on RECIPIENT to license or otherwise make available any of its Intellectual Property Rights or other resources
owned or controlled by it except as expressly provided in this Agreement with respect any Institute Funded IPR. 
 PART 3 

 COMMERCIALIZATION OF PROJECT RESULTS 

Section D3.01 Commercialization Strategy. RECIPIENT shall be under a continuing obligation throughout the term of this Contract to pursue and implement
the commercial development plan submitted with the Application and to provide an annual written report to the INSTITUTE regarding the RECIPIENT’s efforts to commercialize or otherwise bring to practical application Project Results. The
INSTITUTE may, at its option and at any time, provide RECIPIENT with comments regarding the RECIPIENT’s commercial development plan and strategy, in which case RECIPIENT shall consider in good faith the INSTITUTE’s input into such
commercial development plan and strategy. 
 Section D3.02 Commercialization Efforts. The RECIPIENT shall, whether through its own efforts or
the efforts of a licensee under a License Agreement allowed by the terms of this Attachment, use diligent and commercially reasonable efforts to commercialize or otherwise bring to practical application the Project Results in accordance with the
commercial development plan described in Section D3.01. 

  
 Portions of
this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the
Securities Act of 1933, as amended. 

  
 Page D2 

 Section D3.03 Licensing of Project Results. Each License Agreement entered into by the RECIPIENT shall
include an acknowledgement by the licensee that (i) such License Agreement is subject to the INSTITUTE’s licenses, interests and other rights under this Contract, and (ii) to the extent that there is a conflict between the terms of
the License Agreement and the terms of this Contract, the terms of this Contract shall prevail. In addition, all License Agreements shall include terms obligating the licensee to report to the RECIPIENT such information as is required for the
RECIPIENT to fully comply with the terms of the Contract, including without limitation the reporting obligations set forth in Attachment E, and to allow RECIPIENT to make the grants specified in Sections D2.02. The RECIPIENT shall monitor the
performance of its licensees and such licensees’ compliance with the terms of the License Agreements and shall take commercially reasonable actions to enforce the terms of all License Agreements. The RECIPIENT shall promptly report to the
INSTITUTE any material breach of a License Agreement relating to or affecting any of the material provisions of this Contract. 
 Section D3.04
Cost of Licensing Activities. The INSTITUTE shall not be responsible for, and no Grant funds may be used to pay for, any costs or expenses associated with the RECIPIENT’s Licensing Activities. 

Section D3.05 Survival. The licenses, rights and obligations set forth in this Attachment D shall survive any termination of this Contract, including
any termination for convenience by RECIPIENT, except in the event that RECIPIENT pays the Buyout Amount as set forth in Part 4, in which case the licenses, rights and obligations set forth in this Attachment D shall automatically terminate. 

Section D3.06 RECIPIENT Opt-Out. RECIPIENT may, after diligently attempting to comply with the terms of Section D3.02, notify the INSTITUTE in writing
that it is electing to cease its efforts, either directly or through a licensee, to commercialize or otherwise bring to practical application any particular Project Results. Such written notice must identify the applicable Project Results, provide a
reasonable explanation of the reasons for RECIPIENT’s election, including any feasibility studies, trial results, regulatory impediments, financial analyses or similar assessments, and must identify any deadlines in relation to the applicable
Project Results that then exist. Upon receipt of such notice, the INSTITUTE shall have the option, but not the obligation, to exercise its rights in Section 5.01 in relation to the subject Project Results at the INSTITUTE’s expense. The
INSTITUTE shall notify the RECIPIENT in writing within thirty (30) days of its receipt of the RECIPIENT’s notice if the INSTITUTE elects to exercise its rights in relation to the subject Project Results. In the event that the INSTITUTE
exercises its option under this section, the RECIPIENT shall fully cooperate with the INSTITUTE’s efforts, in commercializing or otherwise bringing to practical application the applicable Project Results. 

PART 4 
 REVENUE
SHARING 
 Section D4.01 Revenue Sharing; Buyout. 

(a) Royalties. RECIPIENT shall pay to INSTITUTE as follows: 
  

	 	(i)	 A royalty at the rate of five percent (5%) of Net Sales of Product. The royalty rate shall remain unchanged
until cumulative royalties, including any royalties for combination products as described herein under subsection (ii) and Follow-On Products as described herein under subsection (iii), and sublicense, acquisition and other related fees
received by INSTITUTE total 115% of the Net Grant Award Proceeds (such amount hereinafter referred to as the “Preferenced Return”). Once the Preferenced Return is achieved, the royalty rate shall decline to three percent (3%)

  
 CONFIDENTIAL
TREATMENT MATERIAL 

  
 Page D3 

 CONFIDENTIAL TREATMENT REQUESTED 

 

	 	
of Net Sales of Product (in jurisdictions with a Valid Patent Claim) and one and one half percent (1.5%) of Net Sales in jurisdictions without a Valid Patent Claim. 

 

	 	(ii)	In the event that a Product is sold for a single price in combination with another therapeutically active ingredient(s), or other product(s) or service(s) for which no royalty would be due hereunder if sold separately,
Net Sales from such combination sales for purposes of calculating the royalty amounts payable by RECIPIENT to the INSTITUTE under this Section shall be calculated by multiplying the Net Sales of the combination product by the fraction A/(A + B),
where A is the average gross selling price during the previous calendar quarter of such Product sold separately and B is the gross selling price during the previous calendar quarter of the other therapeutically active ingredient(s), or other
product(s) or service(s). In the event that separate sales of such Product or such additional therapeutically active ingredient(s), or other product(s) or service(s) were not made during the previous calendar quarter, then the Net Sales shall be
reasonably allocated between such Product and such active ingredient(s), or other product(s) or service(s) based upon their relative values. 

  

	 	(iii)	RECIPIENT shall pay to the INSTITUTE a royalty at the rate of three percent (3%) on Net Sales of Follow-On Products. The royalty rate for Follow-On Products specified herein does not change once the Preferenced
Return is attained. 

 (b) Sub-licensing, Acquisition and Other Related Fees. RECIPIENT shall pay to INSTITUTE [***] of
sublicense fees and other fees related to any Sub-license Income [***]. 
 (c) Buyout Trigger Event. Notwithstanding anything to the
contrary in this Section D4.01, upon RECIPIENT’s written notice of the Buyout Notice Trigger Event to INSTITUTE at any time after the Termination Date (the “Buyout Notice”), RECIPIENT may, in lieu of paying any
additional royalties to INSTITUTE pursuant to Section D4.01(a) and (b), pay to INSTITUTE the dollar amount set forth in the following table opposite the applicable period in which such Buyout Notice is delivered (the applicable dollar amount being
referred to as the “Buyout Amount”): 
  

			
	 Period in Which Buyout Notice is
Delivered
	  	 Buyout Amount

	On or prior to the fifth anniversary of the Contract Effective Date	  	125% of Net Grant Award Proceeds less the aggregate amount of all royalties paid to INSTITUTE pursuant to Section D4.01(a) as of the date of the Buyout Notice.
		
	After the fifth anniversary of the Contract Effective Date but on or prior to the tenth anniversary of the Termination Date	  	150% of Net Grant Award Proceeds less the aggregate amount of all royalties paid to INSTITUTE pursuant to Section D4.01(a) as of the date of the Buyout Notice.
		
	After the tenth anniversary of the Contract Effective Date	  	200% of Net Grant Award Proceeds less the aggregate amount of all royalties paid to INSTITUTE pursuant to Section D4.01(a) as of the date of the Buyout Notice.

  
 Portions of
this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the
Securities Act of 1933, as amended. 

  
 Page D4 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 After satisfaction of its obligations under this Section D4.01(b), RECIPIENT shall have no
further obligation under this Section D4.01. 
 (d) “Net Grant Award Proceeds” means the aggregate amount of
Grant award proceeds advanced to RECIPIENT, net of any Grant award proceeds repaid by RECIPIENT to INSTITUTE, including, without limitation, pursuant to Section 4.07 of the Contract. 

Section D4.02 Adjustments. If any funding sources other than the INSTITUTE (but excluding RECIPIENT) contribute funds, directly or indirectly, to the
research yielding any particular Project Result(s) and such funding sources are legally or contractually entitled to receive royalty based compensation with respect to such Project Result(s) (hereinafter a “Participating Funding
Source”), then the royalty percentages in Section D4.01(a) in effect at any time shall be reduced in proportion to the aggregate amount of funds provided by the INSTITUTE under this Contract in comparison to the aggregate amount of
funds provided by all Participating Funding Sources that contributed to the Project Result and by the INSTITUTE. For the sake of clarity, Participating Funding Sources do not include equity or quasi-equity financing funding sources or debt
arrangements. In calculating such reduced rate, funds from Participating Funding Sources used for Indirect Costs or for any costs of product development, manufacturing, marketing, sales, regulatory approval or similar commercialization activities
shall not be included. In addition, for clarity, the rate shall not be reduced as a result of any funds received from funding sources where such funding sources are not legally or contractually entitled to receive a share of the Revenue with respect
to such Project Result(s). 
 Section D4.03 Statements and Timing of Payments. All payments owed pursuant to this Part 4 shall be made to the
Cancer Prevention and Research Institute of Texas, and are payable on or before the thirtieth day following the end of the calendar quarter in which RECIPIENT receives the Revenue or, in the case of Section D4.04, receives the monetary recovery. For
each payment specified in Section D4.01, the payment shall be accompanied by a statement specifying: (i) the Grant to which the payment relates, (ii) the identities of and amounts funded by all Participating Funding Sources, (iii) the
License Agreements to which the payment relates, (iv) the quantity of all Sales of each Commercial Product and Commercial Service since the last payment, if Sales are applicable to the current payment, (v) the gross consideration from all
such License Agreements and Sales, if Sales are applicable to the current payment, and (vi) the amount of the payment to the Cancer Prevention and Research Institute of Texas. 

Section D4.04 Recoveries in Enforcement Actions. In the event that RECIPIENT receives any monetary recovery from its enforcement of Institute-Funded
IPR against infringement by a third party, then it shall pay to the State of Texas a share of such monetary recovery, including any punitive damages, less the documented fees and expenses that are directly associated with such enforcement and are
paid by RECIPIENT to third parties, at the same rate and in the same manner as it shares Revenue pursuant to Section D4.01 (including any adjustments allowed by Section D4.02). For clarity, if the enforcement action is resolved by way of the
execution of a License Agreement with the infringing third party, such 

  
 Portions of
this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the
Securities Act of 1933, as amended. 

  
 Page D5 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 License Agreement is consistent with the Section D4.01, then this Section D4.04 is not intended to apply to
such License Agreement or the consideration specified therein. 
 Section D4.05 Revenue-Related Records. In addition to satisfying the requirements
of Article IV of the Contract and Section E1.03 of Attachment E, the RECIPIENT shall keep complete and accurate Revenue- related Records until the fourth anniversary of the date of the payment of the last royalty payment owed hereunder, in
sufficient detail to permit the INSTITUTE to confirm the accuracy of the statements delivered to the INSTITUTE under Section D4.03 and the calculation of the royalties owed hereunder. 

Section D4.06 Audit of Revenue-Related Records. Upon at least 15 days’ advance written notice, the RECIPIENT shall permit the INSTITUTE or its
representatives or agents, at the INSTITUTE’s expense, to examine the Revenue-related Records of the RECIPIENT pursuant to Section D4.05. Any such examination shall be conducted during regular business hours of RECIPIENT for the purpose of and
to the extent reasonably necessary to verify the RECIPIENT’s compliance with this Part 4. The rights of the INSTITUTE under this Section D4.06 shall terminate on the fourth anniversary of the date of the payment of the last royalty payment owed
hereunder. In the event that any such examination reveals an underpayment to the INSTITUTE of greater than five percent (5%) of the amounts previously paid by the RECIPIENT to the INSTITUTE, then the RECIPIENT shall reimburse the INSTITUTE for
the cost of such examination. 
 PART 5 

OPT-OUT AND DEFAULT 
 Section
D5.01 RECIPIENT Opt-Out. Upon receipt of RECIPIENT’s notice of its election (i) under Section D1.03 to abandon any Institute-Funded IPR or (ii) under Section 3.06 to cease its efforts to commercialize or otherwise bring to
practical application any particular Project Results, the INSTITUTE shall have the option, but not the obligation, to pursue protection of the applicable Institute-Funded IPR, including directing the filing, prosecution and maintenance of patents
covering the applicable Institute-Funded Inventions and/or to commercialize or otherwise bring to practical application the applicable Project Results, at its own cost, either directly or through one or more licensees. If the INSTITUTE elects to
exercise such option, it shall notify RECIPIENT in writing within thirty (30) days of its receipt of RECIPIENT’s notice and RECIPIENT shall thereafter comply with the terms of Section D5.03. 

Section D5.02 RECIPIENT Default. In the event that the INSTITUTE notifies RECIPIENT in writing of RECIPIENT’s failure to materially comply with
its obligations under Sections D1.03 or D3.02 with respect to any particular Project Results, and RECIPIENT fails to cure such failure within thirty (30) days of such notice, then the INSTITUTE shall have the option, but not the obligation, to
direct the filing, prosecution and maintenance of patents covering the applicable Institute-Funded Inventions and/or to commercialize or otherwise bring to practical application the applicable Project Results, at its own cost, either directly or
through one or more licensees. If the INSTITUTE elects to exercise such option, it shall notify the RECIPIENT in writing of such election and RECIPIENT shall thereafter comply with the terms of Section D5.03. 

Section D5.03 RECIPIENT Cooperation upon Opt-Out or Default. In the event that the INSTITUTE exercises its option under Section D5.01 or D5.02, the
RECIPIENT shall: 
  

	 	(a)	transfer all of its right, title and interest in and to the applicable Project Results to the INSTITUTE or the INSTITUTE’s designee, to the maximum extent allowed by law, including where relevant and necessary to
facilitate the foregoing transfer, requesting and diligently attempting to obtain any approvals required by law or otherwise in relation to such transfer; 

  
 Portions of
this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the
Securities Act of 1933, as amended. 

  
 Page D6 

 CONFIDENTIAL TREATMENT REQUESTED 

 

	 	(b)	to the extent that RECIPIENT is unable to transfer all of its right, title and interest in and to the applicable Project Results to the INSTITUTE as specified in item (1), and subject to any existing third party rights,
RECIPIENT hereby grants to the INSTITUTE an exclusive, royalty- free, perpetual, fully transferable license under the applicable Institute-Funded IPR to Exploit the Project Results for the development, manufacture and sale of Commercial Products and
Commercial Services and for all other purposes reasonably related thereto, provided that the INSTITUTE may exercise the foregoing license rights only after exercising its option under Section D5.01 or D5.02; 

 

	 	(c)	fully cooperate with the INSTITUTE’s efforts, and at the INSTITUTE’s cost, in protecting applicable Institute-Funded Inventions and in commercializing or otherwise bringing to practical application the
applicable Project Results, including making relevant RECIPIENT Personnel (to the extent still then-employed by RECIPIENT), Contractors, Collaborators, records, papers, information, samples, specimens and other materials related to the applicable
Institute-Funded Technology reasonably available for such purposes and executing any documents and taking any further action necessary to fully effectuate the intent of this Section; and 

 

	 	(d)	not take any action that would materially impede the INSTITUTE’s ability to protect the applicable Institute-Funded Inventions. 

If the INSTITUTE exercises its option under Sections D5.01 or D5.02, RECIPIENT shall have no further claim or interest in or to the applicable Project Results
(except as set forth in Part 2 of this Attachment, if applicable) and shall not be entitled to any share of Revenue or any other compensation with respect to such Project Results, except to the minimum extent required by law, if any. To the extent
that the INSTITUTE has exercised its option under Section D5.01 or D5.02 and RECIPIENT is unable to transfer all of its right, title and interest in and to the applicable Project Results to the INSTITUTE as specified in item (1), then the
INSTITUTE’s license set forth in item (2) includes the right, but not the obligation, for the INSTITUTE at its cost to: (i) direct the filing, prosecution and maintenance of patents covering the applicable Project Results, and
(ii) enforce all applicable Institute-Funded IPR relevant to the Project Results against any infringement by a third party. Subject to the statutory duties of the Texas Attorney General, if any, RECIPIENT shall cooperate fully with the
INSTITUTE in any action brought by the INSTITUTE to enforce the Intellectual Property Rights in the applicable Project Results, at the INSTITUTE’s cost, including without limitation, joining the enforcement action in name as a party plaintiff
after all required approvals are obtained; provided that the INSTITUTE or its designee shall have full control over such enforcement action and shall receive and retain all monetary recoveries resulting from such enforcement actions, including any
punitive damages. 
 PART 6 

DEFINITIONS 
 The following terms
shall have the following meaning throughout this Attachment. Other terms may be defined elsewhere in this Attachment. 
 (1) Related Party
— with respect to RECIPIENT, any individual or entity that (a) directly, or indirectly through one or more intermediaries, controls, is controlled by, or is under common control of the RECIPIENT and (b) possesses the
right to use or sub-license Product or Institute-Funded IPR in order to sell Products. For purposes of this definition only, the terms “controls,” “controlled,” and “control” mean, with respect to a controlled entity,
(i) the direct or indirect ability or power to direct or cause the direction of the management and policies of such entity or otherwise direct the affairs of such entity, 

  
 Portions of
this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the
Securities Act of 1933, as amended. 

  
 Page D7 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 
whether through ownership of equity, voting securities, or beneficial interest, by contract, or otherwise, or (ii) the ownership, directly or indirectly, of at least 50% of the voting
securities (or other comparable ownership interest for an entity other than a corporation) of such entity. 
 (2) Authorized Seller —
RECIPIENT, its Collaborators, or their licensees or any other party authorized by RECIPIENT, its Collaborators or their licensees to make a Sale on their behalf. 

(3) Buyout Trigger Event – either (a) delivery by RECIPIENT of written notice to INSTITUTE that RECIPIENT desires to buyout the
obligations under the Contract pursuant to Section D.401(c) or (b) (i) the acquisition, by an independent third party (“the Party”), of substantially all of the assets of RECIPIENT or (ii) the license of all or substantially
all of the Institute-Funded IPR by the Party. 
 (4) Commercial Product – anything that incorporates, is based on, utilizes or is
developed from Project Results and is created by human or mechanical effort or by a natural process and that is capable of being sold, licensed, transferred or conveyed to another party or is capable of otherwise being Exploited or disposed of,
whether in exchange for consideration or not, including without limitation any drug, chemical or biological compound, gene, nucleic acid or nucleic acid sequence, gene therapy, plant, machine, mechanical device, hardware, tool or computer program.

 (5) Commercial Service – any service performed that incorporates, is based on, utilizes or is developed from Project Results. For
clarity, Commercial Service does not include research and development performed by RECIPIENT or its Collaborators. 
 (6) Exclusive License
– a License Agreement under which the specific rights granted to the licensee with respect to the Project Results, including without limitation scope of use and territorial rights, are granted on an exclusive basis. 

(7) Exploit – make, have made, use, sell, offer to sell, import, export or otherwise dispose of, practice, copy, distribute, create
derivative works of, publicly perform or publicly display. 
 (8) Follow-on Products - any other Engineered Toxin Body (ETB) products that
contain a SLT1A subunit of the Shiga-like toxin in combination with a targeted binding domain that binds to, and is directed against, CD20. 
 (9)
Institute-Funded IPR – any and all Intellectual Property Rights in and to Institute-Funded Technology. In no event shall Institute-Funded IPR include any intellectual property rights and/or technology in existence and
owned/controlled by the RECIPIENT prior to the receipt of funds from the INSTITUTE, the listing of such IPR and/or technology in existence and owned/controlled by the RECIPIENT prior to the receipt of funds from the INSTITUTE is attached herein.

 (10) Institute-Funded Invention – an Invention conceived or first reduced to practice by RECIPIENT, RECIPIENT Personnel and/or
Collaborator(s) in the performance of Institute-Funded Activity. 
 (11) Institute-Funded Technology – any and all of the following
resulting or arising from Institute- Funded Activity during the Contract term: (a) proprietary and confidential information, including but not limited to data, trade secrets and know-how; (b) databases, compilations and collections of
data; (c) tools, methods and processes; and (d) works of authorship, excluding all scholarly works, but including, without limitation, computer programs, source code and executable code, whether embodied in software, firmware or otherwise,
documentation, files, records, data and mask works; and all instantiations of the foregoing in any form and embodied in any form, including but not limited to therapeutics, drugs, drug delivery systems, drug formulations, devices, diagnostics,
biomarkers, reagents and research tools. Institute-Funded Technology includes Institute-Funded Inventions. In no event shall Institute-Funded Technology include items that were conceived of, in existence, or owned/controlled by

  
 Portions of
this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the
Securities Act of 1933, as amended. 

  
 Page D8 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 RECIPIENT prior to receipt of funds from the INSTITUTE (a) proprietary and confidential information,
including but not limited to data, trade secrets and know-how; (b) databases, compilations and collections of data; (c) tools, methods and processes; and (d) works of authorship, excluding all scholarly works, but including, without
limitation, computer programs, source code and executable code, whether embodied in software, firmware or otherwise, documentation, files, records, data and mask works; and all instantiations of the foregoing in any form and embodied in any form,
including but not limited to therapeutics, drugs, drug delivery systems, drug formulations, devices, diagnostics, biomarkers, reagents and research tools. 

(12) Intellectual Property Rights - any and all of the following and all rights in, arising out of, or associated therewith: (a) all United
States and foreign patents and utility models and applications therefor, and all reissues, divisions, renewals, extensions, provisionals, and continuations and continuations-in part thereof, and equivalent or similar rights anywhere in the world in
inventions and discoveries; (b) all trade secrets and rights in know-how and proprietary information; (c) all copyrights, copyright registrations and applications therefor, and all other rights corresponding thereto throughout the world;
(d) all mask works, mask work registrations and applications therefor, and any equivalent or similar rights in semiconductor masks, layouts, architectures or topology; and (e) any similar, corresponding or equivalent rights to any of the
foregoing anywhere in the world. 
 (13) Invention – a method, device, process or discovery that is conceived and/or reduced to practice,
whether patentable or not. 
 (14) License Agreement – an agreement by which an owner of a Project Result grants any right to Exploit
such Project Result to another party in exchange for consideration. 
 (15) Licensing Activities – the efforts of RECIPIENT or its
Collaborator to negotiate, execute or enforce a License Agreement. 
 (16) Necessary Additional IPR – any unencumbered Intellectual
Property Rights (a) owned by RECIPIENT, and (b) identified by the Institute and agreed to in writing by RECIPIENT, that are not Project Results but are necessary to Exploit the Project Results for the specific purposes set forth in the
applicable Section of this Attachment D. 
 (17) Net Sales - the gross amount invoiced for such Product by RECIPIENT, its Related Parties, and
sub- licensees to Third Parties, less deductions for: (i) trade, quantity and/or cash discounts, allowances and rebates (including, without limitation, promotional or similar allowances) actually allowed or given; (ii) freight, postage,
shipping, insurance and transportation expenses and similar charges (in each instance, if separately identified in such invoice); (iii) credits or refunds actually allowed for rejections, defects or recalls of such Product, outdated or returned
Product, or because of rebates or retroactive price reductions; and (iv) sales, value-added, excise taxes, tariffs and duties, and other taxes directly related to the sale, to the extent that such items are included in the gross invoice price
(but not including taxes assessed against the income derived from such sale). 
 (18) Non-Exclusive License – a License Agreement under
which the rights granted to the licensee with respect to the Project Results are granted on a non-exclusive basis. 
 (19) Product - Product
is a pharmaceutical product containing MT-3724 or variant thereof that binds to, and is directed against CD20 and/or a pharmaceutical product containing an Engineered Toxin Body (ETB) the development of which was directly funded by CPRIT grant
identification number CC121020. 
 (20) Project Results – any and all Institute-Funded Technology and Institute-Funded IPR. 

  
 Portions of
this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the
Securities Act of 1933, as amended. 

  
 Page D9 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 (21) Revenue – the gross consideration, whether cash or non-cash (e.g., securities, direct
equity interest, indirect equity interest, etc.), received from Sales and License Agreements related to Project Results (including without limitation, any milestone fees, license fees, sublicense fees, assignment fees, product royalties and similar
fees and royalties), net of (a) trade or quantity discounts or rebates, credits, allowances or refunds given for rejected or returned Commercial Products or Commercial Services, (b) any sales, value-added or other tax or governmental
charge levied on the sale, transportation or delivery of a Commercial Product or Commercial Service (but excluding any income tax owed by the RECIPIENT), and (c) any separately stated charges for freight, postage, shipping and insurance. 

(22) Sale – means any sale, lease, transfer, conveyance or other exploitation or disposition of a Commercial Product or Commercial Service
for which consideration is received by an Authorized Seller. 
 (23) Sub-license Income - means payments received by RECIPIENT or its Related
Parties from sublicensees who are not a Related Party in connection with sublicenses granted hereunder to sell Products excluding (a) payments made by a sublicensee to support or fund research and development activities to be undertaken by
RECIPIENT or its Related Parties, (b) payments made in consideration of the issuance of equity or debt securities of RECIPIENT or its Related Parties to the extent that the price paid for such equity or debt does not exceed the then fair market
value thereof and sublicensee to support or fund research and development activities to be undertaken by RECIPIENT or its Related Parties, and (c) royalties paid to RECIPIENT or its Related Parties by such sublicensee on net sales (or, in the
case of a profit-sharing agreement with a sublicensee, profit-sharing payments made to RECIPIENT by such sublicensee) pursuant to the applicable sublicense agreement. 

  
 Portions of
this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the
Securities Act of 1933, as amended. 

  
 Page D10 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 

 
 ATTACHMENT E 

REPORTING REQUIREMENTS 
 This
Attachment E is hereby incorporated into and made a part of that certain CANCER RESEARCH GRANT CONTRACT (“Contract”) by and between the Cancer Prevention and Research Institute of Texas (“CPRIT”
or the “INSTITUTE”) and the RECIPIENT. A capitalized term used in this Attachment shall have the meaning given to term in the Contract or in the Attachments to the Contract, unless otherwise defined herein. In the event of a
conflict between the provisions of this Attachment and the provisions of the Contract, this Attachment shall control. 
 INSTITUTE and RECIPIENT
agree as follows: 
 ANNUAL REPORTING 

Section E1.01 Annual Reports. The RECIPIENT shall submit reports annually to the INSTITUTE within 60 days of the anniversary of the Effective Date of
this Contract or at such other time as may be specified herein. The reports shall be submitted by the means and in the form(s) required by the INSTITUTE and shall be signed by the Principal Investigator/Program Director and the RECIPIENT’s
Authorized Signing Official. To the extent possible, the reports shall only include information that may be shared publicly. However, if it is necessary to submit information in the reports that the RECIPIENT considers confidential in order to fully
comply with the terms of this Contract, then the RECIPIENT shall use reasonable efforts to mark such information as “confidential” and shall, to the extent practicable , to segregate such information within the reports to facilitate its
redaction should redaction ever be necessary or appropriate. 
 Section E1.02 Contents of Reports. Each report shall contain a signed
verification (electronic signature is acceptable) of RECIPIENT’s compliance with each of its obligations as set forth in the Contract and shall include the following for the period covered by such report, as may then be applicable: 

(a) Project Data. During the term of the Contract, RECIPIENT shall include in its annual report each of the following (except that the final annual
report due under this part (a) shall be due within ninety (90) days after the end of the term of the Contract): 
  

	 	(1)	A brief statement of the progress made to under the Scope of Work, including the progress to achieve the Project Goals and Timelines set forth in Attachment A. 

 

	 	(2)	A brief statement of the Project Goals for the twelve months following submission of the report. 

  

	 	(3)	New jobs created in the preceding twelve month period as a result of the Grant funds awarded to RECIPIENT. 

  

	 	(4)	An inventory of the Equipment purchased for the Project using Grant funds. 

  

	 	(5)	A HUB report in accordance with Section 3.08 “Historically Underutilized Businesses” of the Contract. 

(b) Commercialization Data. During the term of the Contract and continuing thereafter for so long as RECIPIENT has ongoing obligations to the INSTITUTE
with respect to protection, development, commercialization and licensing of Project Results pursuant to Attachment D, RECIPIENT shall provide information about commercialization activities in a format specified by the INSTITUTE. 

  
 Portions of
this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the
Securities Act of 1933, as amended. 

  
 Page E1 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 c) Revenue Sharing Data. During the term of the Contract and continuing thereafter for so long as
RECIPIENT has ongoing obligations to the INSTITUTE with respect to revenue sharing pursuant to Attachment D: 
  

	 	(1)	A statement of the identities of the funding sources, amounts and dates of funding for all funding sources for the Project. 

  

	 	(3)	A brief statement of the RECIPIENT’s efforts to secure additional funds to support the Project. 

  

	 	(4)	All financial information necessary to verify the calculation of the revenue sharing amounts specified in Attachment D. 

(d) Additional Data. In addition to the foregoing, RECIPIENT shall use commercially reasonable efforts to also promptly report any other information
required by this Contract or otherwise reasonably requested by the INSTITUTE, the Legislature, or any other funding or regulatory bodies covering the RECIPIENT’s activities under this Contract. 

Section E1.03 Record Keeping and Audits. The provisions of Article IV of the Contract shall apply fully to all information reported to the INSTITUTE
pursuant to this Attachment, except that the right of the State of Texas to audit and the RECIPIENT’s obligation to maintain Records shall continue until four years after the date of each such report made by RECIPIENT hereunder. 

Section E1.04 Confidentiality of Documents and Information. The provisions of Section 2.13 “Confidentiality of Documents and
Information” of the Contract shall apply fully to all Confidential Information reported, delivered or submitted to the INSTITUTE pursuant to this Attachment E. 

  
 Portions of
this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the
Securities Act of 1933, as amended. 

  
 Page E2 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 IN WITNESS THEREOF, THE PARTIES HAVE SIGNED AND EXECUTED IN DUPLICATE COUNTERPARTS ON THE DATES INDICATED.

  

									
	RECIPIENT	  		  	INSTITUTE
					
	By	 	 /s/ Jason Kim
	  		  	By:	 	 /s/ William “Bill” Gimson, Executive Director

	(Signature of Person Authorized to Sign Contracts)	  		  		 	
					
	Name:	 	Jason Kim	  		  	Name:	 	William “Bill” Gimson, Executive Director
	Date:	 	November 7th, 2012	  		  	Date:	 	May 15, 2012

  

			
	 RECIPIENT Mailing Address:
	  	INSTITUTE Mailing Address:
	 111 W COOPERATIVE WAY, SUITE 201,

GEORGETOWN TX 78626
	  	Cancer Prevention and Research Institute of TX
	  	Grant Compliance
		  	P.O. Box 12097
	  	Austin, TX 78711
		
		  	INSTITUTE Physical Address:
	Physical Address: (If different from above)	  	211 E. 7th Street, Suite 300
		  	Austin, TX 78701
		
		  	Phone: (512) 463-3190
		
	Phone: 512-961-8479	  	Fax: (512) 475-2563
	Fax: 512-233-2709	  	

  
 Portions of
this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the
Securities Act of 1933, as amended. 

 CONFIDENTIAL TREATMENT REQUESTED 

 

 

 
 Information Regarding Duplication of Effort and Project Overlap 

To avoid duplicate payments for the same work, please advise CPRIT by indicating below if you have received other grant funding for some or all of the
cancer research/prevention services that are the subject of this award subsequent to submitting the application to the Institute. 
  

	☐	I have received other grant funding for some/all (circle appropriate) not otherwise previously disclosed in my CPRIT grant application ID
                    to support some or all of the research/prevention services that are the subject of the CPRIT award. I have revised my budget
request accordingly to reflect the changes to award amount to avoid duplicate payments. 

  

	☒	I have not received other grant funding to support some or all of the research/prevention services that are the subject of the CPRIT award not otherwise disclosed in my CPRIT application ID CC121020. 

By uploading this document to CPRIT’s electronic grants management system and submitting it for CPRIT approval, the primary investigator/project director
for the project certifies that the information contained herein is correct and should be relied upon by CPRIT in executing the final award contract. 

  
 Portions of
this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the
Securities Act of 1933, as amended.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00272-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00272-of-00352.parquet"}]]